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ABSTRACT 
Traumatic brain injury (TBI) can cause persistent cognitive changes and ongoing 
neurodegeneration in the brain. Accumulating epidemiological and pathological 
evidence implicates TBI in the development of Alzheimer’s disease (AD). Furthermore, 
repetitive TBI is shown to cause the neurodegenerative condition chronic traumatic 
encephalopathy, which has many clinical and pathological similarities to AD.  
AD is characterized by three main pathological hallmarks: extracellular plaques 
composed of beta-amyloid (Aβ), dystrophic neurites and intracellular neurofibrillary 
tangles composed of tau. The amyloid cascade hypothesis posits that the accumulation 
of Aβ in the brain is a principal factor in AD pathogenesis, and genetic mutations 
causing enhanced Aβ formation result in early-onset AD.  
Aβ plaques have been demonstrated in approximately 30% of severe TBI cases, 
however the effects of mild/moderate non-fatal TBI on Aβ plaque deposition remains 
unclear. Furthermore, the underlying mechanisms and risk factors for Aβ plaque 
deposition after TBI are unknown. Thus, this thesis investigated the effects of a single 
TBI on the onset and progression of Aβ plaque deposition in the APPswe/PS1dE9 
(APP/PS1) transgenic mouse model of AD.  
Two models of TBI were utilized in this thesis. The first model was a focal cortical 
brain injury, which involved the insertion of a needle into the somatosensory cortex of 
the brain, inducing localized structural brain damage with minimal secondary 
pathology. The results demonstrated that focal cortical brain injury before the onset of 
plaque deposition and mid-way into deposition did not alter Aβ plaque load post-injury. 
Furthermore, these studies indicated that APP/PS1 mice with established amyloidosis 
have the same microglial, astrocytic and synaptic responses to focal cortical brain injury 
as wild type mice, despite the presence of AD-related neuropathology.  
The second model of TBI utilized in this thesis was the lateral fluid percussion injury 
(LFPI) which produces widespread diffuse brain damage with evolving secondary 
pathology such as diffuse axonal injury (DAI). These studies demonstrated that LFPI 
prior to the onset of Aβ plaque deposition caused an increase in plaque load after injury, 
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whereas LFPI during Aβ plaque deposition caused a decrease in plaque load post-
injury. Thus, the results indicated that the stage of amyloidosis at the time of LFPI 
affected whether Aβ plaque deposition was enhanced or reduced in APP/PS1 mice after 
injury. Furthermore, as LFPI but not focal cortical brain injury altered Aβ plaque 
deposition after injury, the results indicate that diffuse TBI may be required for the 
modulation of Aβ plaque deposition after injury.  
DAI can result in impaired axonal transport and the intra-axonal accumulation of 
amyloid precursor protein (APP). Impaired axonal transport is caused by TBI-induced 
cytoskeletal damage and may be a potential mechanism for post-injury Aβ plaque 
formation. Neurofilaments are an integral part of the axonal cytoskeleton and undergo 
various pathological changes following TBI however, the role of NF in DAI and 
impaired axonal transport is unclear. Thus, the final study in this thesis investigated the 
effect of altering the NF cytoskeleton on the axonal response to injury. The results 
demonstrated that genetically altered mice lacking NF light gene showed an increased 
number of axonal APP accumulations, indicating higher levels of impaired axonal 
transport and thus DAI following LFPI. 
The research in this thesis provides insight into the effects of different types of TBI on 
Aβ plaque dynamics. The results indicated that diffuse but not focal TBI can alter Aβ 
plaque deposition after injury and that this modulation is dependent on the stage of 
amyloidosis at the time of injury. Lastly, this thesis demonstrated that the axonal 
cytoskeleton is important in the axonal response to TBI and may be a potential 
therapeutic target.  
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1 Introduction 	
1.1 Traumatic brain injury 
A traumatic brain injury (TBI) is commonly induced by an impact to the head or 
by acceleration/deceleration and/or rotational forces. The major causes of TBI in 
high-income countries are motor vehicle accidents and falls (Baguley et al., 
2012, Feigin et al., 2013, Myburgh et al., 2008). It is typically a prime of life 
disability, affecting predominantly younger individuals during their most 
productive years of life (Maas et al., 2008, Feigin et al., 2013). However, in 
recent decades, the median age of TBI patients has increased in high-income 
countries (Maas et al., 2008, Roozenbeek et al., 2013). This may be attributed to 
increased life expectancy and thus an increase in the ‘aging’ of the population as 
well as better traffic safety (Maas et al., 2008, Roozenbeek et al., 2013). The 
main cause of TBI in the elderly is falls, with people aged over 75 years having 
the highest rates of hospitalisations and deaths (McIntyre et al., 2013).  
 
Severe TBI may lead to profound disability or even death, whereas moderate and 
mild forms of TBI can result in significant morbidity and disability (Khan et al., 
2003). TBI can cause both short-term and long-term cognitive deficits. 
Characteristically, these deficits occur in attention, higher order executive 
functions, short-term memory and learning, speech and language functions and 
speed of information processing, reflecting the regions of the brain most 
vulnerable to TBI-induced damage (McAllister, 2011). Moderate to severe TBI 
causes enduring cognitive deficits, whereas deficits from mild TBI may resolve 
within months. However, persistent cognitive disturbances and neurobehavioural 
symptoms occur in up to 15-30% of mild TBI cases (reviewed in Shenton et al., 
2012). Additionally, evidence suggests that (single or repetitive) TBI can lead to 
ongoing neurological decline including the development of conditions such as 
chronic traumatic encephalopathy (CTE) (Corsellis et al., 1973, Martland, 1928, 
McKee et al., 2009) and Alzheimer’s disease (AD) (Mortimer et al., 1991, 
Fleminger et al., 2003).  
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1.2 The epidemiological link between traumatic brain injury and 
Alzheimer’s disease 
Several epidemiological studies have concluded that a history of TBI increases 
the risk of AD (Heyman et al., 1984, French et al., 1985, Sullivan et al., 1987, 
Graves et al., 1990, Mortimer et al., 1991, Mayeux et al., 1993, Kondo et al., 
1994, Rasmusson et al., 1995, O'Meara et al., 1997, Schofield et al., 1997, Guo et 
al., 2000, Fleminger et al., 2003, Wang et al., 2012, Plassman et al., 2000), 
although others have shown no such relationship (Amaducci et al., 1986, Shalat 
et al., 1987, Chandra et al., 1989, Broe et al., 1990, Li et al., 1992, Fratiglioni et 
al., 1993, Tsolaki et al., 1997, Mehta et al., 1999, Launer et al., 1999). Many of 
these studies may be limited by small sample sizes and thus a lack of statistical 
power to detect an association (Button et al., 2013). In support of this notion, 
meta-analyses by Mortimer et al. (1991) and Fleminger et al. (2003) have both 
shown statistically significant associations between TBI and AD, but only for 
males. This increased risk of AD after TBI in males but not females is also 
reported in other independent studies (O'Meara et al., 1997, Salib and Hillier, 
1997). Conversely, a study by Mayeux et al. (1993) has demonstrated an 
association between head injury and AD in females only, although it may have 
included insufficient males to detect an association. It is important to note, 
however, that TBI is three times more common in men than in women (Khan et 
al., 2003, Nemetz et al., 1999), which may be a confounding factor.  
 
Another variable that may determine whether TBI increases an individual’s risk 
of AD is injury severity. For example, epidemiological studies have variously 
defined TBI as head injury with loss of consciousness (LOC) (Fratiglioni et al., 
1993, Mayeux et al., 1995), head injury with LOC >15 minutes (Broe et al., 
1990), head injury requiring medical care and/or LOC (O'Meara et al., 1997) and 
head injury causing memory loss, confusion or coma (Amaducci et al., 1986). 
Plassman and colleagues demonstrated in a cohort of Navy and Marine veterans 
that moderate (LOC or post-traumatic amnesia > 30 minutes but < 24hrs) and 
severe (> 24 hours), but not mild (< 30 minutes), TBI increased the risk of AD 
(Plassman et al., 2000). Additionally, Schofield et al. (1997) found that TBI 
increased the odds of developing AD only if LOC is more than 5 minutes; 
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similarly, Guo et al. (2000) found that only TBI with LOC significantly 
increased AD risk. Thus, a particular level of injury severity may be required to 
initiate and/or accelerate the development of AD pathology.  
 
Due to the identification of several risk factor genes in the development of AD, 
the interaction between genetics, TBI and AD has also been the focus of several 
studies. The strongest identified genetic risk factor for AD is the gene encoding 
apolipoprotein E (APOE), with inheritance of the ε4 allele increasing the risk of 
developing the disease relative to the ε3 allele (Pericak-Vance et al., 1991, 
Strittmatter et al., 1993). Studies have demonstrated that TBI is only significantly 
associated with AD in the presence of the APOE ε4 allele (Mayeux et al., 1995, 
Katzman et al., 1996) and that there is a 10-fold increase in the risk of AD 
following TBI in association with the ε4 allele (Mayeux et al., 1995). 
Additionally, it has been reported that the frequency of the ε4 allele is higher in 
TBI cases with AD or mild cognitive impairment (MCI) compared to TBI cases 
without AD and TBI-/AD-free controls (Mauri et al., 2006). This suggests that 
TBI and APOE ε4 may act synergistically in the development of AD. However, 
other studies have shown no additive or synergistic effects between APOE ε4 
and TBI in increasing the relative risk of AD (O'Meara et al., 1997, Mehta et al., 
1999) and there is evidence that those lacking the APOE ε4 allele are at a higher 
risk of developing AD following TBI compared to those carrying the allele (Guo 
et al., 2000, Jellinger et al., 2001a, Jellinger et al., 2001b).  
 
Several studies have also shown that a family history of AD, which may indicate 
a genetic predisposition, does not augment the relative risk of developing the 
disease after TBI (Mayeux et al., 1995, Mortimer et al., 1991, Guo et al., 2000, 
van Duijn et al., 1992, Mayeux et al., 1993).  Thus, TBI may instead be a risk 
factor for the more common sporadic form of AD. In contrast, a study by Nemetz 
et al. (1999) demonstrated there was no increase in the incidence of AD in a TBI 
cohort (as compared to a population-based incidence rate) however, the observed 
time to AD onset was significantly less than the expected time (as determined 
using a life table based on a TBI-free AD cohort) (Nemetz et al., 1999). This 
suggests that TBI may not necessarily increase the risk of developing AD, but 
might accelerate the disease process in predisposed individuals. However, studies 
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by Mortimer et al. (1991), Rasmusson et al. (1995) and Guo et al. (2000) showed 
no effect of TBI on the age of AD onset.  
   
Overall, the epidemiological data indicates that TBI may increase the risk of 
developing AD (Fleminger et al., 2003, Mortimer et al., 1991) and may 
accelerate its onset in some cases (Nemetz et al., 1999). To elucidate the 
underlying mechanisms we must understand the pathology of TBI and AD, and 
how they may be related.  
 
1.3 The pathology of Alzheimer’s disease 
AD is a neurodegenerative disorder causing progressive cognitive decline. The 
AD brain is characterised by three main pathological hallmarks: extracellular 
amyloid beta (Aβ) plaques, intracellular neurofibrillary tangles composed of 
hyperphosphorylated tau (Braak and Braak, 1991) and dystrophic neurites 
(Woodhouse et al., 2009, Dickson and Vickers, 2001). The Aβ peptide is derived 
from the proteolytic cleavage of a larger protein called the amyloid precursor 
protein (APP). Two proteolytic pathways exist by which APP can be processed: 
a non-amyloidogenic pathway where cleavage by α-secretase then γ-secretase 
produces the peptides sAPPα, p3 and the amyloid intracellular domain (AICD); 
and an amyloidogenic pathway in which cleavage by β-secretase then γ-secretase 
produces Aβ, sAPPβ and AICD. Several sites within APP can be cleaved by γ-
secretase, producing Aβ peptides ranging from 38 to 43 amino acids in length, 
with Aβ40 and Aβ42 being the most common (reviewed by O'Brien and Wong, 
2011).  
 
Increased Aβ production via the amyloidogenic pathway is hypothesised to 
underlie, at least in part, the series of neurodegenerative changes associated with 
AD (Hardy & Allsop, 1991). Several mutations resulting in familial AD have 
been identified in the APP gene (Goate et al., 1991, reviewed in Bagyinszky et 
al., 2014). Many of these mutations are near the γ-secretase and β-secretase 
cleavage sites and cause aberrant processing of APP, leading to increased 
formation of Aβ (reviewed in Bagyinszky et al., 2014). Additionally, mutations 
in the genes presenilin 1 and 2 (PS1 and PS2), which are components of the γ-
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secretase complex, also result in familial AD (reviewed in Bertram and Tanzi, 
2008, Sherrington et al., 1995). These mutations cause increased production of 
the more amyloidogenic Aβ42 peptide relative to the Aβ40 peptide, leading to 
Aβ aggregation and plaque formation (Duff et al., 1996, Jankowsky et al., 2004).  
 
The APP and thus Aβ protein sequence is highly conserved throughout species 
(Podlisny et al., 1991), however, the rodent Aβ sequence has 3 amino acid 
differences at residues 5, 10 and 13 (Yamada et al., 1987). Normally, a 
proportion of aged humans and mammals including primates, dogs, pigs and 
polar bears develop Aβ plaques (Selkoe et al., 1987, Johnstone et al., 1991) 
whereas aged rodents do not (Selkoe, 1989). Experimental evidence has 
demonstrated that rodent Aβ does not aggregate as readily as human Aβ 
(Kirschner et al., 1987, Kirkitadze et al., 2001, Otvos et al., 1993) and this may 
be why rodents do not form plaques with aging. Thus, to study the mechanisms 
of Aβ plaque formation and associated pathology, transgenic mouse models of 
Alzheimer’s amyloidosis have been created. These mice typically overexpress 
human APP with familial AD mutations and develop plaques composed of 
human Aβ (Hall and Roberson, 2012).  
 
1.4 The pathology of traumatic brain injury 
Head trauma can result in two main forms of brain damage, focal and diffuse, 
however, both can occur simultaneously. Moderate and severe cases of TBI, 
involving severe direct impact to the brain, causes focal damage such as 
intracranial bleeds, lacerations and cortical and subcortical contusions 
(Andriessen et al., 2010, Adams et al., 1991). Diffuse injury, however, does not 
necessarily involve a direct hit to the head and thus can occur in mild, moderate 
and severe TBI’s (Andriessen et al., 2010). Diffuse injury is multifocal and 
caused by the straining, shearing and compression of brain tissue (Adams et al., 
1989, Adams et al., 1991, Strich, 1956, Holbourn, 1943, Holbourn, 1945, Strich 
and Oxon, 1961). This results in pathology such as diffuse axonal and vascular 
injury, brain swelling and hypoxic-ischemic injury (Andriessen et al., 2010). 
Diffuse axonal injury (DAI) is the most common pathology seen and occurs due 
to acceleration/deceleration forces on the brain causing shear stress to axons 
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(Adams et al., 1982, Gennarelli et al., 1982, Strich, 1956, Strich and Oxon, 
1961).  
 
Two common types of DAI that occur in brain injury are ‘bulbs’ and 
‘varicosities’. Axonal bulbs appear as a single large swelling, still in continuation 
with either the proximal (proximal axonal bulb) or the distal axonal segment 
(distal axonal bulb) (Hanell et al., 2014). Axonal varicosities are swellings that 
occur periodically along intact neurites (Hanell et al., 2014, Tang-Schomer et al., 
2012). Both types of axonal pathology have been suggested to reflect the force 
distribution along the axon at the time of injury (Smith and Meaney, 2000). 
Varicosities are thought to occur in axons that have experienced a uniform strain 
along their length, whereas bulbs occur in axons that have undergone a highly 
localized area of strain, causing axonal disconnection (Smith and Meaney, 2000).  
 
These swellings are caused by interrupted axonal transport, resulting in the 
accumulation of incompletely transported proteins and organelles (Tang-
Schomer et al., 2010, Tang-Schomer et al., 2012).  Such transport deficits may be 
due to the stretching of axons, which results in the breakage, disorganization and 
disassembly of microtubules, a component of the axonal cytoskeleton (Tang-
Schomer et al., 2012, Tang-Schomer et al., 2010). The accumulation of proteins 
and organelles following progressive damage to the neuronal cytoskeleton may 
eventually lead to disconnection of the axon via secondary axotomy, 
subsequently forming an axonal bulb (Tang-Schomer et al., 2010, Smith and 
Meaney, 2000). It is believed that the disconnected distal axon will then undergo 
Wallerian degeneration (Smith and Meaney, 2000). However, in some axons 
there are periodic breaks of individual microtubules causing only partial 
interruption of axonal transport and the formation of varicosities (Tang-Schomer 
et al., 2012). It is possible that intact axons with varicosities may undergo repair 
if cytoskeletal integrity can be restored. 
 
Although transport deficits and swellings do not occur in all axons, other 
important pathological changes induced by TBI can cause axonal dysfunction 
and/or degeneration. Diffuse brain injury can lead to the compaction of 
neurofilaments (NFs), another component of the axonal cytoskeleton (Povlishock 
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et al., 1997, Pettus et al., 1994). It has been proposed previously that NF 
compaction and microtubule disassembly were both parts of the same 
progressive pathology ultimately leading to impaired axonal transport 
(Povlishock and Pettus, 1996, Pettus et al., 1994).  However, current evidence 
now suggests that, in the majority of injured axons, NF compaction is not 
associated with impaired axonal transport and swelling, and thus is a different 
injury phenotype (Stone et al., 2001, Marmarou et al., 2005).  
 
TBI can also perturb the axonal ionic balance, including elevated intra-axonal 
sodium and calcium levels (Wolf et al., 2001, Kilinc et al., 2009). Elevated intra-
axonal calcium levels can activate certain proteases, such as calpain (Kilinc et 
al., 2009, Iwata et al., 2004), which can damage the axonal cytoskeleton and ion 
channels (Iwata et al., 2004, Kilinc et al., 2009, McGinn et al., 2009). 
Additionally, TBI-induced oxidative stress and lipid peroxidation can cause 
cytoskeletal degradation and mitochondrial dysfunction in the axon (reviewed in 
Johnson et al., 2013b). 
 
Enduring axonal pathology has been seen years after TBI (Chen et al., 2009). 
Axonal injury is a significant pathology in both TBI and AD and thus may be an 
important mechanistic link between these conditions.  
 
1.5 Pathological links between traumatic brain injury and Alzheimer’s 
disease 
The axonal responses to TBI and AD are pathologically similar. Dystrophic 
neurites surrounding Aβ plaques have been shown to have accumulations of NF 
protein aggregates, organelles and tau (Stokin et al., 2005, Woodhouse et al., 
2009, Dickson and Vickers, 2001). Furthermore, Stokin et al. (2005) found 
impaired axonal transport resulting in axonal swellings in both AD transgenic 
mouse models and early AD. These swellings occurred in areas of the brain 
devoid of amyloid and morphologically resembled those seen in axonal injury 
and senile plaque-associated dystrophic neurites (Stokin et al., 2005).  
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As mentioned previously, Aβ is cleaved from its precursor protein APP by the 
proteolytic enzymes γ-secretase (incorporating PS1) and β-secretase (BACE) 
(reviewed in O'Brien and Wong, 2011).  Fast anterograde axonal transport, 
mediated by kinesin-I, traffics APP along with PS1 and BACE, during which 
APP may be cleaved to form Aβ (Kamal et al., 2001). Reducing kinesin-I in an 
AD mouse model has been shown to increase axonal swellings and overall levels 
and deposition of Aβ in the brain (Stokin et al., 2005). This indicates that 
impaired axonal transport could be an early initiating event in Aβ plaque 
development and the pathogenesis of AD. As TBI causes widespread axonal 
injury, including axonal transport deficits, this could be a mechanism by which 
TBI triggers Aβ plaque deposition and the development of AD.  
 
1.5.1 Traumatic brain injury and intra-neuronal accumulation of APP 
The accumulation of APP in axons following TBI is now well recognized as a 
pathological hallmark of axonal injury (Gentleman et al., 1993, Otsuka et al., 
1991, Sherriff et al., 1994). Otsuka et al. (1991) first showed the accumulation of 
APP following a cortical stab wound injury in rats. APP immunoreactivity was 
demonstrated in dystrophic axonal swellings as early as 30 minutes post-injury 
and in glial cells resembling astrocytes at 3 hours post-injury (Otsuka et al., 
1991). Shortly after, Gentleman et al. (1993) confirmed this result in human post-
mortem brain tissue from cases of severe head injury. APP immunoreactivity 
was demonstrated in neuronal cell bodies and dystrophic neurites of the cortical 
grey matter and in damaged axons of the white matter (Gentleman et al., 1993).  
 
The presence of APP within damaged axons has now been extensively described, 
in both human TBI cases (Gentleman et al., 1993, Sherriff et al., 1994, McKenzie 
et al., 1996) and multiple rodent TBI models, including mild compression 
contusion trauma (Lewen et al., 1995), fluid percussion injury (FPI) (Bramlett et 
al., 1997, Pierce et al., 1996, Iwata et al., 2002) and controlled cortical impact 
(CCI) injury (Ciallella et al., 2002). Extensive axonal APP accumulations are 
found in white matter following injury, matching the pattern of DAI detected by 
silver staining (Gentleman et al., 1993, Sherriff et al., 1994, McKenzie et al., 
1996). Furthermore, these APP-immunoreactive axons demonstrate the features 
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of DAI, including undulating morphologies, varicose swellings and axonal end 
bulbs (Tang-Schomer et al., 2012).  
 
In severe human TBI, axonal APP immunoreactivity is present as early as 35 
minutes post-injury (Al-Sarraj et al., 2004), with the amount of immunoreactivity 
increasing with post-injury survival time (McKenzie et al., 1996). APP is present 
within axonal bulbs, which progressively increase in number and size post-injury 
(Sherriff et al., 1994, McKenzie et al., 1996). Additionally, axonal APP 
accumulations have been shown to persist for years after a single TBI, indicating 
ongoing axonal pathology and neurodegeneration (Roberts et al., 1994, Chen et 
al., 2009, Johnson et al., 2012). TBI does not need to be severe for this pathology 
to arise, with milder forms of non-fatal head injury in humans still showing APP 
accumulation within injured axons (Blumbergs et al., 1994). However, animal 
models have shown that as injury severity increases, so too does the number of 
APP-immunoreactive axonal swellings (Bramlett et al., 1997, Tran et al., 2011a).  
 
Upregulation of APP mRNA and protein following TBI has been demonstrated 
in multiple experimental models, and is part of the acute response of the brain to 
trauma (Murakami et al., 1998, Van den Heuvel et al., 1999, Masumura et al., 
2000, Ciallella et al., 2002). The function of APP is largely unknown, although 
APP’s cleavage product sAPPα has been shown to be neuroprotective after TBI 
(Thornton et al., 2006). Additionally, the APP cleavage product, AICD, is 
proposed to be a transcriptional regulator (Rajendran and Annaert, 2012). Thus, 
following TBI, APP may be upregulated to exert a neuroprotective effect and/or 
regulate genes involved in the acute post-trauma reaction. Conversely, increased 
levels of APP in conjunction with its localized accumulation in axonal swellings, 
may lead to enhanced Aβ generation and accumulation.  
 
1.5.2 Traumatic brain injury and intra-neuronal accumulation of beta-
amyloid 
In addition to APP, Aβ has also been shown to accumulate in neurons post-TBI. 
Axonal Aβ accumulations have been described in post-mortem brain samples 
from both short- and long-term TBI-survivors (Chen et al., 2009, Uryu et al., 
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2007, Smith et al., 2003) as well as in animal models of TBI (Smith et al., 1999, 
Iwata et al., 2002, Chen et al., 2004, Abrahamson et al., 2006, Tran et al., 2011a, 
Tran et al., 2011b).  
 
In animal models of TBI including parasagittal FPI (Iwata et al., 2002), rotational 
acceleration injury (Chen et al., 2004, Smith et al., 1999) and CCI (Abrahamson 
et al., 2006, Tran et al., 2011a, Tran et al., 2011b), A accumulation has been 
demonstrated in axonal swellings and end bulbs in the injured cortex, 
pericontusional white matter, hippocampus and dentate gyrus. Additionally, Aβ 
has also been shown to accumulate within neuronal cell bodies of the cortex and 
the hippocampus (Iwata et al., 2002). Several studies have noted Aβ 
accumulation in axons and neurons after TBI in APPNLh/NLh (APPK670N/M671L 
knocked in to endogenous APP gene), 3xTg-AD (APPK670M/N671L, 
PSEN1M146L, TauP301L) and APP/PS1 (APPK595N/M596L, PSEN1dE9) 
transgenic mouse models of AD, but not in wild-type controls (Abrahamson et 
al., 2006, Tran et al., 2011a, Tran et al., 2011b). Notably, other groups have also 
shown this pathology in brain injured wild-type mice and rats (Iwata et al., 2002, 
Murai et al., 1998).  
 
Accumulated intra-neuronal Aβ has been detected as early as one hour and as 
late as one year post-injury in animal models of TBI (Iwata et al., 2002, Tran et 
al., 2011b). The size and number of Aβ accumulations increases across the first 
24 hours post-injury (Tran et al., 2011b) and the total number of Aβ-positive 
axonal swellings increases with injury severity (Tran et al., 2011a).  
 
Following TBI, Aβ co-accumulates with APP, BACE and PS1 in axonal bulbs 
(Chen et al., 2009, Uryu et al., 2007), and amyloidogenic processing of APP is 
enhanced. For example, in a rodent CCI model, increased mRNA and protein 
expression of BACE-1 was seen in the ipsilateral cortex and hippocampus, along 
with elevated levels of its cleavage product sAPP (Blasko et al., 2004). An 
increase in Aβ production via BACE-1 APP cleavage has also been shown in 
3xTg-AD mice following CCI injury. Thus, TBI appears to augment 
amyloidogenic processing of APP, leading to Aβ accumulation within injured 
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neuronal cell bodies and axons. Studies in both human AD cases and AD 
transgenic mouse models have demonstrated the accumulation of Aβ 
intraneuronally before the appearance of plaques (Takahashi et al., 2002, Billings 
et al., 2005, Gouras et al., 2000). Thus, the TBI-induced accumulation of Aβ may 
seed plaque formation if it is focally released into the brain parenchyma from 
axonal swellings or lysing cells. Relatedly, in a swine model of TBI, Aβ plaques 
were shown to be in close proximity to Aβ-positive axonal bulbs (Chen et al., 
2009).  
 
1.5.3 Beta-amyloid plaque deposition following traumatic brain injury  
Numerous studies have shown the presence of Aβ plaques in the brain from 
hours up to years following TBI (Roberts et al., 1991, 1994, Nicoll et al., 1995, 
Smith et al., 2003, Ikonomovic et al., 2004, Uryu et al., 2007, DeKosky et al., 
2007, Chen et al., 2009, Johnson et al., 2012). However, only about 30% of 
individuals dying after a severe TBI demonstrated Aβ plaques (Roberts et al., 
1991, 1994), suggesting that other factors such as the location or type of TBI, as 
well as genetic background, may influence the development of plaques post-
injury. The frequency of the APOE ε4 allele has been shown to be significantly 
higher in a Aβ plaque-positive TBI group at post-mortem as compared to a 
plaque-negative TBI group (Nicoll et al., 1995). Furthermore, there was a gene-
dose effect, with the proportion of TBI cases with Aβ deposits increasing with 
the number of ε4 alleles (Nicoll et al., 1995).  
 
Aβ plaques have been observed in cases of non-fatal TBI up to 47 years post-
injury (Johnson et al., 2012). However, due to the advanced age of many of these 
cases, it is unclear whether the plaques were due to the TBI sustained or a 
product of pathological aging and/or prodromal AD. Johnson and colleagues 
(2012) described plaques in both TBI cases and age-matched controls (without a 
history of TBI, neurodegenerative or neurological disease), with no significant 
difference in the incidence of plaque pathology between the two groups (Johnson 
et al., 2012). Nevertheless, the density of plaques was higher in the TBI cases, 
and were often fibrillar, unlike control cases in which they were mostly diffuse 
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(Johnson et al., 2012) thus, TBI may have accelerated the progression of Aβ 
pathology. 
 
Despite reports of TBI-induced Aβ deposition in individuals as young as 10 
years old (Roberts et al., 1994), the ageing brain appears to be more vulnerable to 
Aβ plaque pathology post-injury. One study found that the incidence of plaques 
increased with advancing age in both TBI and control cohorts, however the TBI 
cohort had more plaques and a higher plaque-positivity rate than the control 
cohort (Roberts et al., 1994). This indicates that TBI and pathological aging may 
synergistically increase abnormal Aβ burden in the brain.  
 
Recent advances in neuroimaging using carbon 11-labelled Pittsburgh compound 
B ([11C]PiB) positron emission tomography (PET) allows researchers to detect 
Aβ deposits within the brains of living subjects following TBI. A significant 
increase in the [11C]PiB distribution volume ratio was reported in the cortical 
grey matter of TBI patients within 1 year of their injury compared to controls, 
indicating the presence of  Aβ deposits in these patients (Hong et al., 2014). 
[11C]PiB imaging has also demonstrated that MCI and a history of head injury 
are associated with higher global brain amyloid levels compared to MCI with no 
history of head injury, although this association was not found in cognitively 
normal people with a history of head injury (Mielke et al., 2014), supporting the 
hypothesis that TBI may accelerate AD progression in predisposed individuals. 
These and future studies using this technique will provide evidence for a cause 
and effect mechanistic link between TBI and AD. 
 
1.5.4 Beta-amyloid plaque deposition in animal models of traumatic brain 
injury 
Despite studies demonstrating Aβ plaques in human cases of TBI, no non-
transgenic rodent TBI models have recapitulated these findings (Pierce et al., 
1996, Iwata et al., 2002, Bramlett et al., 1997, Ciallella et al., 2002, Masumura et 
al., 2000). Thus, to assess the relationship between TBI and AD, transgenic 
mouse models of Alzheimer’s amyloidosis have served as a useful tool. The 
results of these studies, however, have been conflicting with increased (Uryu et 
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al., 2002), decreased (Nakagawa et al., 1999, Nakagawa et al., 2000) and no 
change in plaque pathology (Smith et al., 1998) reported following experimental 
TBI. Several factors have complicated the comparison of these studies, including 
the transgenic mouse model used, the age and stage of plaque deposition at the 
time of injury, the timepoints analysed post-injury and the severity and method 
of injury used. The most commonly used experimental TBI model for examining 
the effect of brain injury on A plaque pathology is the CCI, however other 
models, including rotational acceleration injury and FPI have also been used. 
This injury involves the intact dura being hit at a certain depth and speed by a 
pneumatically or electromagnetically controlled piston (reviewed in Xiong et al., 
2013). This model causes a primarily focal injury with elements of DAI to 
underlying white matter tracts (reviewed in Morales et al., 2005).  
 
Many studies have focused on chronic changes in plaque burden or distribution 
after the usual onset of plaque deposition in injured AD-transgenic mice, and 
therefore reveal the effects of TBI on the progression of amyloidosis. Studies on 
PDAPP (APP V717F) mice subjected to CCI injury prior to the onset of 
amyloidosis have shown no change in the number or distribution of Aβ plaques 
at 2 months post-injury (Smith et al., 1998) but a decreased abundance of plaques 
when examined at 8 months post-injury (Nakagawa et al., 1999). Similarly, 
PDAPP mice with overt amyloidosis at the time of CCI injury had an ongoing 
reduction in plaques when examined from 1-16 weeks after injury (Nakagawa et 
al., 2000). In contrast to these studies, Uryu et al. (2002) demonstrated that both 
single and repetitive modified CCI prior to the onset of amyloidosis increases 
plaque burden at 16 weeks post-TBI in Tg2576 (APP K670M/N671L) mice, 
however repetitive injury was shown to increase plaque burden to a greater 
extent than single injury.  
 
The effect of TBI on the onset of plaque pathology has also been examined in a 
number of different transgenic AD mouse models. For example, Tran and 
colleagues have demonstrated no Aβ plaque deposition at 1 to 24 hours or at 7 
days after CCI injury in pre-plaque 3xTg-AD mice, or 24 hours after injury in 
pre-plaque APP/PS1 mice, despite extensive intra-axonal Aβ accumulation (Tran 
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et al., 2011a, Tran et al., 2011b). This indicates that although TBI can cause 
intra-axonal Aβ accumulation in mouse models of TBI, it does not cause Aβ 
plaque formation acutely after injury. A more recent study reported cloudy 
Aβ42-positive accumulations within the injured cortex of a pre-plaque 3xTg-AD 
mouse, 24 hours post-injury, although only in 1 of 7 mice examined (Washington 
et al., 2014).  
 
Studies have also been performed using transgenic mouse models which do not 
spontaneously form Aβ plaques, including the YAC mouse which expresses 
wild-type human APP at levels 2-fold higher than endogenous mouse APP 
(Murai et al., 1998) and the APPNLh/NLh mouse which expresses mutant human 
APP at normal levels under the endogenous mouse APP promoter (Reaume et 
al., 1996). CCI injury was not sufficient to induce plaque formation in either 
APPNLh/NLh mice at 24 hours post-injury (Abrahamson et al., 2006) or YAC mice 
1 week after injury (Murai et al., 1998).  
 
Mouse models have also been used to determine the effect of APOE alleles on 
plaque deposition post-TBI. Hartman et al. (2002) performed CCI injury on 
PDAPP mice expressing human APOE ε4, human APOE ε3 or no APOE at 9-10 
months of age. Three months after injury (12-13-months of age), all groups had 
Aβ-immunoreactive deposits, but only APOE ε4 expressing mice had 
thioflavine-S-positive deposits. Additionally, PDAPP APOE ε4 mice had 
significantly more Aβ-immunoreactive plaques in the molecular layer of the 
dentate gyrus compared to PDAPP APOE ε3 mice (Hartman et al., 2002). These 
results support the notion that APOE genotype may affect Aβ plaque dynamics 
and thus AD progression post-TBI.  
 
Despite the lack of plaques observed in the brains of injured wild-type rodents, 
and the variable results demonstrated in injured transgenic AD mouse models, 
studies in swine have shown Aβ deposition similar to that seen in human TBI 
cases within days, and up to months, post-injury. Aβ plaque-like deposits were 
found in the grey and white matter of pigs following non-impact head rotational 
acceleration brain injury, although only in 30% of injured animals (Smith et al., 
1999, Chen et al., 2004). This is in general accordance with human studies, in 
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which only 30% of TBI sufferers are shown to have Aβ deposits post TBI 
(Roberts et al., 1991, Roberts et al., 1994). Interestingly, the TBI-induced 
plaques were located in the white matter of pigs with the most extensive axonal 
pathology (Smith et al., 1999) suggesting a relationship between axonal injury 
and Aβ deposition. Additionally, some of these plaques were shown to be 
fibrillar in nature, staining with both thioflavin-S and Congo red (Chen et al., 
2004). The amino acid sequence of the Aβ peptide in pigs is homologous to the 
human sequence, and thus these studies demonstrate that diffuse TBI can cause 
Aβ plaque-like aggregates in mammals with human Aβ (Johnstone et al., 1991).  
 
From these studies it is apparent that TBI can affect Aβ plaque dynamics in 
animal models. Whether TBI results in increased or decreased plaque formation 
post-injury, and which factors may influence this effect, remain to be elucidated. 
The mechanism of Aβ deposition, source of Aβ and possible degradation of Aβ 
plaques by injury-activated glia and enzymes, all require further investigation 
and clarification. Animal models of experimental TBI will provide a useful 
platform for the continued investigation of post-injury plaque deposition. 
 
1.6 Beta-amyloid clearance after traumatic brain injury 
Following TBI, multiple mechanisms may contribute to clearance of 
accumulated Aβ. However, if clearance mechanisms are defective or become 
overwhelmed by the amount of Aβ produced, then initiation of the amyloid 
cascade and the development of AD may ensue. Mechanisms for Aβ removal 
after TBI may include enzymatic degradation by neprilysin (Iwata et al., 2000), 
phagocytosis by activated glia (Funato et al., 1998, Simard et al., 2006, Wyss-
Coray et al., 2003a) and the more recently described glymphatic system (Iliff et 
al., 2012).  
 
1.6.1 Neprilysin 
Many enzymes within the brain can degrade Aβ, such as neprilysin, insulin-
degrading enzyme, endothelin-converting enzymes, matrix metalloproteinases 
and plasmin (reviewed in Miners et al., 2008). Of these, neprilysin has been the 
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most extensively studied in TBI. Neprilysin is a cell-surface 
metalloendopeptidase (Turner et al., 2001) and is a major extracellular Aβ-
degrading enzyme in the brain (Iwata et al., 2000). Polymorphisms in the 
neprilysin gene may increase the risk for AD (Helisalmi et al., 2004, Sakai et al., 
2004, Shi et al., 2005) and reduced neprilysin mRNA and protein levels were 
observed in the AD brain (Yasojima et al., 2001), particularly in areas 
susceptible to Aβ plaques (Yasojima et al., 2001, Akiyama et al., 2001, Caccamo 
et al., 2005).  
 
Studies in neprilysin-knockout mice have shown a gene-dose dependent increase 
in brain Aβ levels (Iwata et al., 2001). Furthermore, intracerebral injection of a 
lentiviral vector expressing human neprilysin decreases Aβ plaques by half in the 
treated hemisphere compared to the untreated hemisphere in AD transgenic 
mouse models (APPV717F and APP V717I/K670M/N671L) (Marr et al., 2003). 
These studies provide evidence that changes in the activity and levels of 
neprilysin in the brain may alter Aβ clearance, and thus could be an important 
determinant of Aβ plaque formation post-TBI. In support of this notion, a study 
by Chen and colleagues has demonstrated extensive neprilysin immunoreactivity 
in neurons and a virtual absence of Aβ plaques in long-term survival cases of 
TBI (1 month to 3 years) despite the presence of plaques in short-term survival 
cases of TBI (< 1 week survival) (Chen et al., 2009). This suggests that 
neprilysin up-regulation may be an Aβ removal mechanism in the brain 
following TBI. 
 
As noted above, only 30% of TBI cases exhibit Aβ plaques (Johnson et al., 2012, 
Roberts et al., 1991, Roberts et al., 1994), suggesting that other factors such as 
genetics may influence post-TBI plaque deposition. The neprilysin gene has a 
19-22 GT-repeat polymorphism in its promoter region (Sodeyama et al., 2001). 
Numerous studies (Wood et al., 2007, Lilius et al., 2003, Sodeyama et al., 2001) 
have examined whether this polymorphism alters the risk of developing AD, 
with the study by Sakai et al. (2004) showing a positive association. 
Accordingly, a study by Johnson et al. (2009) has demonstrated that the length of 
the neprilysin GT-repeat polymorphism affects acute post-TBI Aβ plaque 
deposition. Specifically, cases with more than 41 total repeats in two alleles, or 
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22 in at least one allele, had an increased risk for Aβ plaques after injury, 
whereas having 20 repeats in one allele was independently associated with 
reduced plaque deposition (Johnson et al., 2009). 
 
These studies indicate that neprilysin may be important in post-injury Aβ 
degradation. Polymorphisms in the neprilysin gene (Sodeyama et al., 2001) and 
other factors affecting its expression and activity may increase susceptibility to 
AD following TBI.  
 
1.6.2 Glia   
Another possible mechanism of plaque removal post-TBI is via activated glia. 
TBI results in neuroinflammation characterized by the activation of microglia 
and astrocytes (reviewed in Kumar and Loane, 2012). Following activation, 
microglia proliferate and are recruited to the site of injury. Activated microglia 
can assume a phagocytic phenotype, and release cytokines and other soluble 
factors, which may be pro- or anti-inflammatory (reviewed in Loane and Byrnes, 
2010).  
 
In addition to microglial activation, peripheral macrophages migrate into the 
brain after injury (reviewed in Kumar and Loane, 2012). These macrophages are 
morphologically indistinguishable from microglia, and currently no markers exist 
to differentiate between them (Loane and Byrnes, 2010). Thus, studies of TBI 
may be examining either cell type and therefore, from herein, this chapter will 
refer to both cell types as microglia.  
 
In response to the cytokines and molecules induced by TBI and produced by 
activated microglia, astrocytes become activated (astrogliosis) (reviewed in 
Zhang et al., 2010). Astrogliosis is characterized by the proliferation, migration 
and hypertrophy of astrocytes (reviewed in Sofroniew, 2009). Both microglia 
(Liu et al., 2010, Paresce et al., 1996) and astrocytes (Funato et al., 1998, Wyss-
Coray et al., 2003a) have been shown to internalize Aβ. Thus, following TBI, 
activated microglia and astrocytes may phagocytose newly formed and 
accumulated Aβ. In support of this notion, Aβ-immunoreactive glial cells of 
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unidentified lineage have been shown in human TBI (Ikonomovic et al., 2004). 
Additionally, in animal models of TBI, microglia have been shown to be 
immunoreactive for Aβ (Chen et al., 2004) and the aforementioned Aβ-degrading 
enzyme, neprilysin (Chen et al., 2009).  
 
Despite the ability of glia to remove Aβ from the brain (Funato et al., 1998, Liu 
et al., 2010, Paresce et al., 1996, Wyss-Coray et al., 2003a), they have also been 
demonstrated to have detrimental effects following TBI (Kumar and Loane, 
2012, Parachikova et al., 2010). Neuroinflammation has been shown to persist 
chronically after TBI (Johnson et al., 2013a, Gentleman et al., 2004) and may 
cause neurodegeneration and the development of AD.  
 
1.6.3 The glymphatic system 
The glymphatic system is a brain-wide pathway used for the transport of fluid 
and the removal of interstitial solutes from the brain (Iliff et al., 2012). 
Subarachnoid cerebrospinal fluid (CSF) enters the brain interstitium via influx 
from the para-arterial space surrounding arteries, and interstitial fluid (ISF) is 
cleared into spaces around large-diameter draining veins (Iliff et al., 2012). The 
convective flow of CSF from the para-arterial space into the interstitium is 
facilitated by the water channel aquaporin 4 (AQP4), expressed on the astrocytic 
endfeet wrapping the space (Iliff et al., 2012). Waste products are forced away 
from arteries and towards the veins as the CSF and ISF exchange (Iliff et al., 
2012). The ISF containing the waste products then enters the paravenous space 
and exits the brain (Iliff et al., 2012). This pathway is responsible for the removal 
of 40-80% of large proteins and solutes from the brain (Nedergaard, 2013). In 
addition to the glymphatic system, a lymphatic system has recently been 
identified in the brain (Louveau et al., 2015). Lymphatic vessels line the dural 
sinuses and transport immune cells and fluid from the CSF to the deep cervical 
lymph nodes (Louveau et al., 2015). It is suggested that these lymphatic vessels 
transport CSF to the periphery following drainage of ISF from the brain 
parenchyma to the CSF by the glymphatic system (Louveau et al., 2015).  
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AQP4 expression is highly polarized to the endfeet of astrocytes and AQP4 
knock-out mice have a 70% reduction in the rate of interstitial solute clearance 
from the brain compared to wild-type mice (Iliff et al., 2012). Additionally, 
AQP4 deletion results in a 55% reduction in Aβ clearance from the brain (Iliff et 
al., 2012). AQP4-mediated glymphatic clearance is clearly important for the 
removal of soluble Aβ, and dysregulation of this pathway could potentiate post-
TBI Aβ clearance following TBI, hence, leading to its accumulation.  
 
TBI causes astrocytes to activate, changing their morphology and molecular 
make-up (reviewed in Sofroniew, 2009). Severe TBI can lead to the formation of 
a glial scar (reviewed in Sofroniew, 2009) whereas more moderate forms can 
cause widespread and long-lasting reactive astrogliosis, which has been observed 
up to 1 month post-injury (Ren et al., 2013). As AQP4 is expressed by 
astrocytes, alterations in its expression are common in TBI-induced reactive 
astrogliosis (Higashida et al., 2011, Marmarou et al., 2014). An investigation by 
Ren et al. (2013) of mild and moderate TBI found that up to 1 month following 
mild TBI, AQP4 expression in astrocytes localizes to the soma rather than the 
endfeet (Ren et al., 2013). This loss of AQP4 polarity could greatly impair the 
clearance of interstitial solutes, leading to the build-up of waste products and Aβ 
in the brain.  
 
The ageing mouse brain has a reduced capacity to clear intraparenchymally 
injected Aβ, due in part to widespread astrogliosis and the loss of AQP4 
perivascular polarization along penetrating arterioles (Kress et al., 2014). This 
reduced glymphatic capacity may potentiate age-related Aβ deposition in the 
brain. Reductions in glymphatic Aβ clearance due to ageing may also act 
synergistically with TBI to increase the Aβ burden in the brain. In support of this 
notion, a post-mortem study has shown that the number of plaque-positive TBI 
cases increase with advancing age (Roberts et al., 1994).  
 
These studies demonstrate that the glymphatic system potentially plays an 
important role in the removal of Aβ from the interstitium of the brain. Following 
TBI, astrogliosis and the dysregulation of this system may result in reduced 
clearance of Aβ. Additionally, increased production of Aβ due to TBI-induced 
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changes in APP processing may overwhelm the capacity of the glymphatic 
system to remove Aβ.  
 
1.7 Chronic traumatic encephalopathy 
This review has concentrated on the effects of a single TBI on Aβ dynamics and 
the development of AD. However, repetitive brain trauma can cause the 
development of the neurodegenerative condition CTE, which shares many 
clinical and pathological features with AD (Corsellis et al., 1973, McKee et al., 
2009). Clinical presentations of CTE include cognitive changes such as 
dementia, behavioural and psychiatric changes and Parkinson-like symptoms 
(McKee et al., 2009). Pathologically, CTE is characterized by brain atrophy, 
astrocytic tau tangles, TDP-43 accumulation as well as the pathological 
hallmarks of AD, tau-neurofibrillary tangles, and in some cases Aβ plaques 
(McKee et al., 2009, Stein et al., 2015, McKee et al., 2013). CTE is defined 
pathologically as a tauopathy, with the abnormal tau accumulations occurring 
primarily perivascularly and at the depths of the cortical sulci (McKee et al., 
2009, McKee et al., 2013). This pattern of abnormal tau accumulation is distinct 
from other tauopathies, however, the neurofibrillary tangles and Aβ plaques are 
immunohistochemically identical to those seen in AD (McKee et al., 2009). 
Additionally, CTE frequently occurs in conjunction with other neurodegenerative 
disorders including AD (McKee et al., 2013). A recent study has characterized 
Aβ plaque deposition in CTE and has found that it occurs in approximately 50% 
of cases (Stein et al., 2015). Furthermore, its findings suggested that CTE with 
Aβ plaques is a more aggressive and distinct subtype of the disease, with a 
greater amount of tauopathy and worse clinical outcome (Stein et al., 2015). The 
overlap between CTE and AD suggests a common underlying pathogenesis 
between these neurodegenerative conditions. 
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Figure 1.1 A dynamics following TBI. TBI results in the accumulation of APP 
and A within axonal swellings. Accumulated A may then be released from 
the axon, into the brain parenchyma, if it undergoes degeneration and lyses. This 
A may then aggregate forming plaques or be cleared via several mechanisms 
including: enzymatic degradation by neprilysin, phagocytosis by microglia 
and/or astrocytes and AQP4-mediated glymphatic clearance.  
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1.10 Project Aims 
 
The balance of epidemiological and pathological studies supports the hypothesis 
that TBI is a risk factor for the development of AD, however, the cellular basis 
for this remains to be elucidated. Additionally, the effect of TBI on the onset and 
progression of AD pathology and the response of the brain to trauma in the 
setting of AD-associated neurodegeneration are unknown. Examining the 
underlying mechanisms by which TBI causes the development of AD will result 
in a greater understanding of the disease etiology, and may lead to the 
identification of therapeutic targets to intervene in the process. Thus, this thesis 
investigated how TBI affects Aβ plaque pathology dependent on the stage of 
amyloidosis at the time of injury, as well as how the brain responds to TBI in the 
setting of amyloidosis. The effect of alterations in the NF cytoskeleton on the 
axonal response to TBI was also evaluated.  
 
For Aims 1 and 2 of this thesis the APPSWE/PSENdE9 (APP/PS1) mouse model 
of AD was used, which replicates some, but not all, aspects of human AD. The 
APP/PS1 mouse model is an early Aβ plaque model (reviewed in Zahs and Ashe, 
2010) and begins depositing a limited number of plaques at 4 months of age, and 
by 6 months of age, plaques are easily detectable (Garcia-Alloza et al., 2006, 
reviewed in Lee and Han, 2013). APP/PS1 mice develop behavioural deficits 
beginning around 6-8 months of age, but do not develop neurofibrillary tangles 
or overt neuronal loss and thus is a model of the pre-dementia phase of AD 
(reviewed in Lee and Han, 2013).  
 
Aim 1: To determine the effect of focal brain injury on beta-amyloid plaque 
deposition, inflammation and synapses. 
The effect of TBI on the onset and progression of Aβ plaque pathology is 
unclear. Additionally, the inflammatory and synaptic responses to TBI in the 
setting of amyloidosis are not well characterized. This aim assesses the effect of 
a focal brain injury model, which causes discrete structural brain damage without 
substantial secondary pathology, on Aβ plaque pathology in APP/PS1 transgenic 
AD mice. Three-month-old pre-plaque APP/PS1 mice, 9-month-old APP/PS1 
Chapter 1 - Introduction 
	 23	
mice with extensive Aβ plaque pathology and wild-type controls of the same 
ages were subjected to focal brain injury, immunohistochemical techniques were 
then used to examine Aβ plaque pathology, inflammation and synaptic changes. 
 
Aim 2: To determine the effect of diffuse brain injury on beta-amyloid 
dynamics.  
Aim 2 employed the lateral fluid percussion injury (LFPI) model to examine the 
effects of a clinically relevant model of diffuse TBI, with more widespread 
secondary pathology than the focal model of Aim 1, on Aβ plaque deposition. 
Three- and 6-month old APP/PS1 mice and 6-month-old wild-type mice were 
subjected to LFPI and immunohistochemical methods were used to assess plaque 
load, APP and Aß relative to axonal pathology and inflammatory changes.  
 
Aim 3: To determine the effect of alterations to the neurofilament 
cytoskeleton on the axonal response to diffuse traumatic brain injury.  
A significant pathology in TBI and a possible mechanism for TBI-induced Aβ 
plaque pathology is DAI. NFs have been proposed to be important in the 
mechanical strength of axons, which is vital in determining how an axon will 
respond to the forces imparted by TBI. Thus, aim 3 examines the effect of 
alterations in the NF cytoskeleton on the axonal response to diffuse TBI. 
Transgenic mice lacking the NF light chain gene (NFLKO) and wild-type mice 
were exposed to LFPI and the axonal response to injury was quantified by 
examining axonal APP accumulations. Furthermore, Western blotting was 
utilized to examine the expression of APP in NFLKO versus wild-type mice after 
TBI. 
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2 Materials and Methods 	
2.1 Mice 
Animals were housed in standard conditions (20°C, 12/12hrs light/dark cycle), 
with access to food and water ad libitum and were monitored daily for signs of 
illness and stress. All experimental procedures were performed in accordance 
with the Australian Code of Practice for the Care and Use of Animals for 
Scientific Purposes and approved by the Animal Ethics Committee of the 
University of Tasmania (A12780, A13170).  
 
2.2 Genotyping 
Tail clippings removed from mice at weaning were incubated in 45ul of 
extraction solution (QUANTA Biosciences, cat no. 95091-025) for 30 minutes at 
95°C to extract genomic DNA. Genotypes were then determined by standard 
PCR using the MyTaqTM Red Mix (Bioline, cat no. BIO-25044) and primers 
(GeneWorks) to the different transgenes and to an internal control gene as per the 
manufacturer’s protocol (refer to Chapter 3 section 3.2.2 and Chapter 5 section 
5.2.2 for specific genotyping information). PCR products and a 100bp ladder 
(Hyperladder V, Bioline, BIO-33031) were then electrophoresed in a 2% agarose 
gel (Bioline, cat no. BIO-41025) with 0.0001% SYBR safe DNA gel stain 
(Invitrogen, cat.no S33102) at 120V for 35 minutes. Gels were then visualized 
using a Carestream 4000MM Pro image station.  
 
2.3 In vivo model of focal brain injury 
In vivo focal brain injury was performed as previously described (King et al., 
2001). Following gas anesthesia (isoflurane 1-3%, 0.7 L/min), mice were given a 
subcutaneous injection of analgesic (Meloxicam, 5mg/kg) and immobilised in a 
Stoelting stereotaxic frame. A burr hole was then progressively drilled into the 
skull over the somatosensory cortex (3 mm lateral, 1 mm posterior to bregma) 
with frequent irrigation using 4°C 0.01M PBS (phosphate buffered saline) to 
cool the site. A 26 gauge needle was then lowered to a depth of 1 mm from the 
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top of the dura into the cortex and left in situ for 10 minutes before being 
removed and the wound sutured closed. Mice were left to recover on a heat pad 
set at 37°C until mobile and feeding.  
 
2.4 In vivo model of diffuse traumatic brain injury 
Mice were subjected to lateral fluid percussion brain injury (LFPI) or sham 
treatment, as described previously (Alder et al., 2011). Briefly, following 
anaesthesia with isoflurane, mice were given a subcutaneous injection of 
buprenorphine (Temgesic, 0.1mg/kg), and the scalp hair removed. Mice were 
then immobilised in a stereotaxic frame (Stoelting, USA). A midline scalp 
incision was made and bupivacaine (0.025%) was applied topically to the skull. 
The periosteum was removed with a scalpel blade and the area in the middle of 
the parietal plate was marked. A 1mm disk of whipper snipper line was attached 
to the skull over the mark with cyanoacrylate glue and surgical glue (Vetbond, 
3M, USA) was applied to the skull to stabilize the sutures and hold the 
surrounding skin away from the craniotomy site. Using the whipper snipper line 
as a guide, a craniotomy was performed using a 3mm (outside diameter) trephine 
attached to a handheld drill. The drilling was done slowly with frequent irrigation 
with 4°C artificial CSF, to cool the skull, remove bone dust and to help release 
the skull bone from the underlying dura. The bone flap was then gently pulled 
from the underlying dura, leaving it intact. An injury hub (a sterile Luer-Loc 
syringe hub cut from a 23 gauge needle) was affixed to the skull using Loctite 
glue and dental cement and then filled with sterile saline. Mice were then 
allowed to recover for 2 hours prior to induction of injury. Injury was induced 
using a fluid percussion device connected to a pressure measurement instrument 
(American Scientific Model FP 302). The animal was re-anaesthetised, the hub 
filled with sterile saline and connected to the fluid filled tube of the injury 
device. Anaesthesia was then removed and the mouse allowed to recover until a 
breathing pattern indicative of light anaesthesia (but not full consciousness) was 
gained. The pendulum of the device was then released transmitting a fluid 
pressure pulse to the intact dural surface. The injury induced was of a mild to 
moderate severity (1.25-1.35 atm). The mice were then removed from the injury 
device, re-anaesthetised with isoflurane and placed back into the stereotaxic 
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frame. The injury hub was removed, the injury site examined and then the skin 
sutured closed. Sham surgeries were performed in the same manner, omitting 
release of the pendulum.  
 
2.5 Tissue preparation 
Mice were terminally anesthetized with sodium pentobarbitone (110mg/kg 
delivered intraperitoneally) and transcardially perfused with 4% 
paraformaldehyde in 0.01M PBS for immunohistochemical studies and in 0.01M 
PBS for biochemical studies. Tissue was then dissected immediately and post-
fixed for 24 hours in 4% paraformaldehyde in 0.01M PBS for 
immunohistochemical studies or snap frozen in liquid nitrogen and stored at        
-80°C for biochemical analyses.  
 
2.6 Immunohistochemistry and histological staining 
2.6.1 Indirect fluorescent immunohistochemistry 
Free-floating brain sections were incubated 3 × 10 minutes in 0.01M PBS with 
0.25% Triton-X-100 followed by Dako serum-free protein block (Dako, cat no. 
X0909) for 15 minutes at room temperature. Sections were then immunolabelled 
with combinations of mouse monoclonal and rabbit polyclonal primary 
antibodies diluted in 0.01M PBS with 0.3% Triton-X-100, for 1 hour at room 
temperature then overnight at 4°C. Following incubation in primary antibodies, 
sections were washed in 0.01M PBS with 0.25% Triton-X-100 6 × 10 minutes. 
Primary antibody labelling was visualized by incubation in Alexa-fluorophore 
conjugated secondary antibodies (Molecular Probes) diluted in 0.01M PBS with 
0.3% Triton-X-100 at 1:1000 for 2 hours at room temperature. Following 
incubation in secondary antibodies, sections without thioflavin-S staining were 
incubated in a solution of 4’,6-diamidino-2-phenylindole (DAPI, 5µg/ml, 
Invitrogen, cat no. D3571) for 10 minutes at room temperature prior to washing. 
Sections were then washed 3 × 10 minutes in 0.01M PBS with 0.25% Triton-X-
100, once in 0.01M PBS, and mounted used Dako fluorescent mounting medium 
(Dako, cat no. 53023).  
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2.6.2 Formic acid antigen retrieval 
For MOAB-2 Aβ plaque labelling, formic acid antigen retrieval was performed. 
Sections were incubated in 88% formic acid (Sigma-Aldrich, cat no. 399388-
500ML, lot. 06098KJ) for 8 minutes at room temperature and then washed in 
0.01M PBS 6 x 5 minutes. Immunohistochemistry was then performed as 
described. 
 
2.6.3 Thioflavin-S staining 
Thioflavin-S (Sigma-Aldrich, cat no. T-1892, lot. 123H0598) staining was also 
used to determine Aβ plaque load. This stain labels a subset of fibrillar and 
dense-core plaques that are composed of Aβ with a β-pleated sheet conformation 
(Dickson and Vickers, 2001, Lindgren and Hammarstrom, 2010). Brain sections 
were incubated in thioflavine-S solution (0.125% thioflavine-S diluted in 60% 
absolute ethanol, 40% 0.01M PBS) for 3 minutes at room temperature. Sections 
were then washed 2 × 1 minute in a 50% absolute ethanol in 50% 0.01M PBS 
solution followed by 3 × 5 minute washes in 0.01M PBS. Immunohistochemistry 
was then performed as outlined above.  
 
2.7 Western Blotting 
2.7.1 Protein extraction  
Frozen brain tissue was transferred immediately into 250ul of RIPA buffer 
(Sigma-Aldrich, R0278-50mL) with protease (Complete Mini Protease Inhibitor 
Cocktail tablets Roche, cat no. 11 836 153 001) and phosphatase inhibitors 
(Phosphatase Inhibitor Cocktail, A.G. Scientific, Inc., P-1549) and homogenized 
using an UltraTurrax. Homogenates were then incubated with shaking for 30 
minutes at 4°C followed by centrifugation at 13000rpm for 15 minutes at 4°C. 
The supernatant was then transferred to a clean tube and the pellet discarded. 
Protein concentration was then determined by performing a Bradford assay as 
per manufacturer’s protocol (BioRad Protein Assay, BioRad, 500-006)  
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2.7.2 Gel electrophoresis and Western Blot 
Gel electrophoresis was performed as per the manufacturer’s protocols (Life 
Technologies). Bolt® 4×Lithium dodecyl sulphate (LDS) sample buffer (Life 
Technologies, cat no. B0007) and 10× Bolt® Sample reducing buffer (Life 
Technologies, cat no. B0009) were added to the protein samples and the samples 
heated at 80°C for 10 minutes. The samples were then loaded onto 4-12% Bolt® 
Bis-TRIS Plus gels (Life Technologies, cat no. NW04125BOX) and 
electrophoresed at 200V for 20 minutes in Bolt® MES running buffer (Life 
Technologies, cat no. B0002). The gels were then transferred at 20V for 1 hour at 
4°C in Bolt® Transfer buffer (Life Technologies, BT0006) to 0.2µm PVDF 
membranes (BioRad, cat no. 162-0177) and blocked in 5% skim milk powder in 
Tris-buffered saline with 0.1% Tween-20 (TBST). The membranes were then 
incubated in the primary antibodies in 5% skim milk powder in TBST for 2 
hours at room temperature, washed 3 × 10 minutes in TBST and then incubated 
in a HRP-conjugated antibody (goat anti-mouse HRP, Dako, cat no. P0447; goat 
anti-rabbit HRP Dako, cat no.P0448) at 1/7000 diluted in 5% skim milk powder 
in TBST for 2 hours at room temperature. The Immobilon™ chemiluminescent 
HRP Substrate (Millipore cat no. WBKL50500) was then used to detect 
immunoreactivity and images were captured using a Carestream 4000MM Pro 
image station. A pre-stained molecular ladder (Thermo Scientific, cat no. 26619, 
lot. 00188551) was used to determine the molecular weights of immunoreactive 
bands.  
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Table 2.1 Primary antibody information 
Name Species Immunogen/ 
Immunoreactivity 
Application Concentration Company Catalogue 
Number 
6E10 M 
IgG1 
Amino acids 1-16 of Aβ. 
Labels Aβ40 and Aβ42 and 
APP. 
 
Immuno 
WB 
1/1000 
1/5000 
Covance SIG-39320 
APP 
C-Terminal 
R C-terminal of human APP 
amino acid 676-695.  
 
Immuno 1/1000 Sigma A8717 
APP R C-terminal human and 
mouse APP.  
 
WB 1/1000 Invitrogen 36-6900 
AT8 M  
IgG1 
Human paired helical 
filament-tau 
(phosphoSer202/ 
phosphoThr205). 
 
Immuno 1/1000 Thermo 
Fisher 
Scientific 
MN1020 
GAPDH M 
IgG1 
Glyceraldehyde-3-
phosphate dehydrogenase.  
 
WB 1/5000 Millipore MAB374 
GFAP R Human brain glial 
fibrillary acidic protein. 
Labels astrocytes.  
 
Immuno 1/2000 Dako 20334 
Iba-1 R Ionized calcium binding 
adaptor molecule 1. Labels 
microglia and 
macrophages. 
 
Immuno 1/1000 Wako 019-19741 
MOAB-2 M 
IgG2b 
N-terminus of Aβ (amino 
acids 1-4). Labels Aβ40 
and Aβ42 (not APP). 
 
Immuno 
WB 
1/2000 
1/5000 
Novus 
Biologicals 
NBP2-
13075 
SMI-32 M IgG1 A non-phosphorylated 
epitope in NFH. Visualises 
neuronal cell bodies, 
dendrites and some thick 
axons. 
 
Immuno 1/2000 Covance SMI-32P 
SMI-312 M IgG1 
cocktail 
Phosphorylated 
neurofilaments. Visualises 
axons. 
 
Immuno 1/2000 Covance SMI-312R 
Synaptophysin R Synaptophysin. 
 
Immuno 1/200 Millipore AB9272 
M, mouse; R, rabbit; Immuno, Immunohistochemistry; WB, Western blotting.  
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Table 2.2 Secondary antibody information 
Emission (nm) Reactivity Species Dilution Supplier, Catalogue Number 
488 M IgG1 G 1/1000 Molecular Probes, A-21121 
546 M IgG2b G 1/1000 Molecular Probes, A-21143 
488 M IgG G 1/1000 Molecular Probes, A-11034 
546 R IgG G 1/1000 Molecular Probes, A-11035 
594 R IgG G 1/1000 Molecular Probes, A-11037 
M, mouse; R, rabbit; G, goat.
Chapter 3 – Results 
	 31	
3 The effect of focal brain injury on Aβ plaque deposition, 
inflammation and synapses 	
3.1 Introduction 
As discussed in Chapter 1, previous studies in AD mouse models have 
demonstrated that the effect of TBI on the onset and progression of Aβ plaque 
deposition is complex and not completely understood. The influence of TBI on 
Aβ plaque dynamics may differ depending on the stage of amyloidosis in the 
model at the time of injury as well as the type of injury model used. Thus, the 
present study aimed to investigate the effects of a focal cortical brain injury on 
Aβ plaque deposition in a transgenic mouse model of AD at stages before the 
onset of plaque deposition and mid-way into deposition. It also investigated, in 
the setting of increased APP production and amyloidosis, whether the microglial, 
astrocytic and synaptic responses to brain injury were altered by comparing 
transgenic APP/PS1 mice to WT mice of the same genetic background.  
 
The focal model of brain injury used in this study involved the acute insertion of 
a fine gauge needle through a small craniotomy to induce a discrete lesion to the 
somatosensory cortex. This injury model was selected to provide a localized 
model of structural brain damage, with a less substantial distribution of 
secondary pathology (eg oedema, inflammatory changes, diffuse axonal injury) 
relative to fluid percussion or impact models. The focal brain injury model has 
been well described and involves a relatively well-defined sequence of cellular 
changes, including the localized proliferation and infiltration of glial cells, tissue 
remodeling, glial scar formation and neovascularization with minimal tissue 
destruction and loss (King et al., 2001, Blizzard et al., 2011, Carbonell et al., 
2005). This model therefore permitted the examination of local changes in Aβ 
plaque deposition, inflammation and synapses surrounding the injury site by 
immunohistochemical techniques.  
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3.2 Materials and Methods 	
3.2.1 Mice 
All experimental procedures utilized male APPSWE/PSENdE9 (APP/PS1) 
(Jankowsky et al., 2001) and C57BL/6 wild-type (WT) littermate control mice at 
either 3- or 9-months of age.  
 
3.2.2 Genotyping 
Genotyping was performed as outlined in the Material and Methods section 2.2. 
To detect the presence of the APP and PS1 transgenes, primers to the PS1 gene 
were utilized and primers to the IL-2 were used as an internal control. The 
primers sequences and expected product sizes are outlined in Table 3.1. 
 
Table 3.1 Primers sequences and expected product sizes.  
Gene Primer sequence Product Size (bp) 
PS1 
forward 5’-AATAGAGAACGGCAGGAGCA-3’ 
reverse 5’-GCCATGAGGGCACTAATCAT-3’ 
608 
IL-2 
Forward 5’-CTAGGCCACAGAATTGAAAGATCT-3’ 
reverse 5’-GTAGGTGGAAATTCTAGCATCATCC-3’ 
324 
 
3.2.3 In vivo model of focal brain injury 
Three- and 9-month-old APP/PS1 and WT controls (n=3-4 mice per group, per 
time-point, 52 total) were subjected to focal brain injury or sham treatment 
(surgery omitting the injury) as outlined in the Materials and Methods section 
2.3. 
 
3.2.4 Tissue preparation 
Mice were terminally anaesthetized, transcardially perfused and tissue was 
prepared for either immunohistochemistry or Western blotting as outlined in the 
Materials and Methods section 2.5.  
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3.2.5 Protein extraction Western Blotting 
Protein extraction and Western blotting with the MOAB-2 and 6E10 antibodies 
was performed as outlined in the Materials and Methods section 2.7 (refer to 
Table 2.1 in the Materials and Methods section for antibody concentrations. For 
each sample 30µg of protein was loaded onto the gel. 
 
3.2.6 Immunohistochemistry 
For immunohistochemical studies, mice were terminally anesthetized and 
transcardially perfused at either 24 hours or 7 days post-injury as outlined in the 
Materials and Methods section 2.5. Serial 50µm tangential sections were then cut 
on a vibratome (Leica VT1000). In each animal 10 tangential sections were 
obtained from the injury site, numbered from the dura inwards, which were 
labelled for MOAB-2 (3,6,8,10), thioflavine-S (4,9), Iba-1 (6,10), GFAP (7) and 
synaptophysin (3) as outlined in the Materials and Methods section 2.6. For 
MOAB-2 Aβ plaque labelling, formic acid antigen retrieval was performed as 
outlined in the Materials and Methods section 2.6.2. For immunolabelling of 
fibrillar Aβ deposits, thioflavin-S was used and for all Aβ, and the recently 
characterized antibody MOAB-2, was used to label mouse and human 
unaggregated, oligomeric and fibrillar forms of Aβ42 and unaggregated forms of 
Aβ40, but not APP from either species (Youmans et al., 2012a, Youmans et al., 
2012b, Perez et al., 2013, Katsouri et al., 2014, Zhao et al., 2014a, Zhao et al., 
2014b), was used. This antibody has previously been demonstrated to have 
strong intra-neuronal and extra-cellular immunoreactivity for Aβ in the 3×Tg 
(APPSWE, MAPTP301L, PSEN1M146V) mouse model of AD (Youmans et al., 
2012a). We therefore used brain tissue from 3×Tg mice as a positive control for 
intra-neuronal Aβ labelling. The antibody SMI-32 which labels non-
phosphorylated epitopes in neurofilament M and H was used to label a subset of 
neurons (Goldstein et al., 1983). For assessment of the microglial response and 
synaptic changes, the antibodies anti-Iba-1 and anti-synaptophysin were used, 
respectively. The astrocytic response was examined using the GFAP antibody 
and the AT8 antibody against hyperphosphorylated tau was used to assess the 
presence of abnormal tau processing after injury. 
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3.2.7 Confocal microscopy and quantification 
Imaging was performed on a Perkin-Elmer Ultraview VOX confocal imaging 
system using Volocity 6.3 software for image capture and processing. For each 
analysis, all images were acquired with the same laser power and exposure 
settings. Plaque loads (percentage area thioflavin-S or MOAB-2 positive) were 
calculated for a 2000x2000µm field of view (20× objective) encompassing the 
injury site, or corresponding area in the sham, from 2 × thioflavin-S stained and 
4 × MOAB-2 immunolabelled sections per mouse. The Multithresholder plug-in 
on ImageJ (NIH, v1.46) was used to automatically segment the image 
(RenyiEntropy method for thioflavine-S and GFAP, Li method for MOAB-2 and 
Iba-1). The percentage area of Iba-1 labelling was calculated for a 500×500µm 
area (20× objective) of the injury site or the corresponding site in the sham on 2 
sections per mouse. Similarly the percentage area for GFAP labelling was 
calculated for a 1000×1000µm (20× objective) of the injury site or the 
corresponding site in the sham on 1 section per mouse. For quantification of 
synaptophysin labelling, 2 images were taken “near” (60µm) and “distant” 
(120µm) to the injury site per section (60× objective). Using ImageJ, blinded to 
case type, images were Gaussian blurred (=1) and thresholded at the same 
level, before puncta were identified using a watershed plugin 
(http://bigwww.epfl.ch/sage/soft/watershed) as previously described (Mitew et 
al., 2013a). Synaptophysin positive puncta between 0.15-1.5µm2 were assessed 
and the number of boutons counted per field (synaptophysin density) and the 
percentage area covered was recorded.  
 
3.2.8 Statistical analysis 
All data was analyzed using IBM SPSS Statistics (Version 19). For thioflavin-S 
and MOAB-2 plaque load data, a two-way analysis of variance (ANOVA) model 
with the factor variables treatment (injury, sham) and post-treatment time (24 
hours, 7 days) was used.  The microglial data was examined using ANOVA for 
the main effects of the four factor variables: treatment (injury and sham), post-
treatment time (24 hours and 7 days), age (3 months and 9 months) and genotype 
(APP/PS1 and WT). A full factorial ANOVA was then used to test for 
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interactions between the variables. The synaptophysin data was also analyzed 
using ANOVA methods for the main effects of the four factor variables: 
treatment (injury and sham), post-treatment time (24 hours and 7 days), distance 
from injury site (near and distant) and genotype (APP/PS1 and WT), followed by 
a full factorial ANOVA. All data is reported as means ± standard error of the 
mean (SEM), with significance set at p<0.05 and estimates of effect size (partial 
η2) reported for significant effects. 
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3.3 Results 	
3.3.1 Verification of the MOAB-2 antibody 
To confirm the specificity and labelling pattern of the MOAB-2 antibody, we 
performed co-labelling with the commonly used anti-Aβ antibody 6E10 in 
APP/PS1 mouse brain tissue (see Figure 3.1A).  Western blotting was also 
performed on 9-month-old APP/PS1 and WT cortical tissue to ensure the 
MOAB-2 antibody was specific for Aβ and did not cross-react with full length 
APP (Figure 3.1B).  
 
3.3.2 Aβ plaque load in 3-month-old APP/PS1 mice 
Three-month-old APP/PS1 mice were used to examine the effects of focal brain 
injury on plaque deposition prior to the onset of frank amyloidosis. A very small 
number of MOAB-2 positive Aβ plaques were present in sections from injured 
and sham APP/PS1 mice at both 24 hours and 7 days post-injury. No change in 
plaque deposition was detected in injured mice compared to sham mice 
following focal brain injury at either 24 hours or 7 days post-injury (Figure 3.2). 
Although plaques were present in the brains of these mice, they were rare in the 
area used for quantification, and so plaque load was not quantified. Furthermore, 
no intra-neuronal or intra-axonal accumulations of MOAB-2 labelled Aβ were 
detected at any time-point (Figure 3.2). As the MOAB-2 antibody has been 
shown previously to label intra-neuronal Aβ in 3×Tg mice (Youmans et al., 
2012a), we used brain tissue from these mice as a positive control. MOAB-2 
labelled intra-neuronal Aβ in the brain tissue of 3×Tg mice as expected (Figure 
3.2).  
 
3.3.3 Aβ plaque load in 9-month-old APP/PS1 mice 
Nine-month-old APP/PS1 mice had established amyloidosis, with plaques that 
labelled with both thioflavin-S and the Aβ antibody, MOAB-2. Following focal 
brain injury the thioflavin-S plaque load surrounding the injury site was not 
significantly different (p>0.05) to the corresponding area in sham mice at either  
Figure 3.1 Verification of the MOAB-2 antibody. (A) Co-immunolabelling 
with MOAB-2 and 6E10 in 9-month-old APP/PS1 cortex. MOAB-2 (red) and 
6E10 (green) plaque labelling co-localised. Scale bar = 200μm. (B) MOAB-2 
and 6E10 immunoblots of cortical brain samples from 9-month-old APP/PS1 
and WT mice. MOAB-2 and 6E10 both labelled Aβ and only 6E10 labelled 
APP.
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Figure 3.2 Focal brain injury does not induce intra-neuronal Aβ 
accumulations in 3- or  9-month-old APP/PS1 mice,  or Aβ plaques in 
3-month-old mice at 24 hours or 7 days post-injury. 3xTg tissue was 
used as a positive control for intra-neuronal Aβ. Representative sections 
labelled with the Aβ antibody MOAB-2 (red), the neuronal antibody 
SMI-32 (green) and the nuclei marker DAPI (blue). Aβ plaques can be 
seen in 9-month-old injured mice, but no intra-neuronal or intra-axonal 
Aβ accumulation can be seen. * Marks the injury site. Scale Bar = 50μm.
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24 hours (0.09 ± 0.02% vs 0.10 ± 0.04%) or 7 days (0.14 ± 0.07% vs 0.08 ± 
0.02%) post-injury (Figures 3.3A and B). The MOAB-2 plaque load surrounding 
the injury site in APP/PS1 mice was also not significantly different (p>0.05) to 
the corresponding area in sham mice at either 24 hours (3.72 ± 0.99% vs 3.03 ± 
0.55%) or 7 days post-injury (2.71 ± 0.40% vs 2.70 ± 0.23%) (Figures 3.3A and 
B). Additionally, no intra-neuronal or intra-axonal accumulations of Aβ were 
observed in injured or sham brains at either time-point stained with thioflavin-S 
or MOAB-2 (Figure 3.2).  
 
3.3.4 Aβ plaque dynamics in wild-type mice 
Focal injuries in WT mice were also examined with MOAB-2 and thioflavin-S 
staining. As expected, no plaques were present at either 24 hours or 7 days post-
injury in sections from WT mice injured at either 3- or 9-months of age (Figure 
3.4). Furthermore, no intra-neuronal or intra-axonal accumulations of Aβ were 
detected at either time-point (Figure 3.4).  
 
3.3.5 Hyperphosphorylated tau 
As previously described in other transgenic mouse models of AD (Woodhouse et 
al., 2009), AT8-immunoreactivity was detected in a subset of dystrophic neurites 
surrounding Aβ plaques in APP/PS1 mice (Figure 3.5). However, no AT8-
immunoreactivity was detected around the injury site in either APP/PS1 or WT 
mice (Figure 3.5). 
 
3.3.6 Microglial/macrophage response 
The microglial/macrophage response following focal cortical brain injury was 
examined at 24 hours and 7 days post-injury in 3- and 9-month-old WT and 
APP/PS1 mice. The sham treatment did not cause visible microglial proliferation 
and/or activation at either 24 hours or 7 days post-injury (Figure 3.6A). The 
percentage areas occupied by Iba-1-positive microglia/macrophages are 
presented in Table 3.2. There was a significant main effect of treatment [F(1,47) 
= 72.2, p<0.001, partial η2 = 0.61] with injury increasing the percentage area  
Figure 3.3 Focal brain injury does not effect Aβ plaque deposition in 9-month-
old APP/PS1 mice. (A) Representative sections stained with thioflavin-S or 
labelled with the Aβ antibody MOAB-2. Dotted yellow line indicates injury 
site. Scale bar = 200μm. (B) There was no significant difference (p>0.05) 
in thioflavin-S plaque load between injured and sham APP/PS1 mice at 
either 24 hours or 7 days post-injury. (C) There was no significant difference 
(p>0.05) in MOAB-2 plaque load between injured and sham APP/PS1 mice 
at either 24 hours or 7 days post-injury. Bars represent mean ± standard error.
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Figure 3.4 Focal brain injury does not induce Aβ plaques or intra-neuronal 
accumulations of Aβ in WT mice at 24 hours or 7 days post-injury. 
Representative sections labelled with the Aβ antibody MOAB-2 (red), the 
neuronal antibody SMI-32 (green) and the nuclei marker DAPI (blue). * 
Marks the injury site. Scale bar = 50μm.
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Figure 3.5 Focal brain injury does not induce hyperphosphorylated 
tau in APP/PS1 or WT mice. Representative sections labelled with the 
hyperphosphorylated tau antibody AT8 (green) and the Aβ antibody 
MOAB-2 (red). AT8-positive dytrophic neurites (yellow arrows) can be 
observed surrounding Aβ plaques. Scale bars = 50μm.
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occupied by Iba-1-positive microglia/macrophages compared to sham (Figures 
3.6A, B and C). There was also a significant main effect of post-treatment time 
[F(1,47) = 25.7, p<0.001, partial η2 = 0.35] with the percentage area occupied by 
Iba-1-positive microglia/macrophages higher at 7 days post-injury compared to 
24 hours post-injury (Figures 3.6A, B and C). A significant treatment×time 
interaction was observed [F(15,1) = 25.7, p<0.001, partial η2 = 0.42] with the 
percentage area occupied by Iba-1-positive microglia/macrophages higher at 7 
days post-injury compared to 24 hours post-injury, in injured but not sham mice 
(Figures 3.6A, B and C). There were no significant main effects or interactions 
for genotype or age (p>0.05) (Figures 3.6A, B and C).  
 
Table 3.2 Percentage of area covered by Iba-1-positive microglia/macrophages 
(means ± SEM) 
Genotype Treatment Age Time-point Area (%) 
 
APP/PS1 
 
Injury 3 months 24 hours 
7 days 
15.0 ± 1.1 
24.7 ± 2.1 
9 months 24 hours 
7 days 
13.0 ± 1.7 
27.1 ± 4.6 
Sham 3 months 24 hours 
7 days 
8.90 ± 0.48 
10.3 ± 0.76 
 9 months 24 hours 
7 days 
8.52 ± 0.67 
9.96 ± 0.89 
WT 
Injury 3 months 24 hours 
7 days 
14.2 ± 1.6 
21.5 ± 2.1 
9 months 24 hours 
7 days 
12.2 ± 3.5 
24.8 ± 2.7 
Sham 3 months 24 hours 
7 days 
10.2 ± 0.69 
10.2 ± 0.52 
 9 months 24 hours 
7 days 
8.80 ± 0.40 
9.70 ± 0.58 
 
 
  
Figure 3.6 APP/PS1 mice have the same microglial/macrophage response 
to focal brain injury as WT mice. (A) Representative sections labelled with 
Iba-1 for microglia. At 24 hours post-injury microglia/macrophages have 
an activated phenotype and local migration has occurred resulting in the 
accumulation of microglia/macrophages at the edge of the injury site in both 
APP/PS1 and WT mice of both ages. By 7 days post-injury a large accumulation 
of activated microglia/macrophages can be seen at the injury site. Scale bar 
= 200μm. (B) There was a significant increase (p<0.001) in the percentage 
area Iba-1-positive in 3-month-old injured mice compared to sham mice at 
both 24 hours and 7 days post-injury. There was also a significant increase 
(p<0.001) in injured mice at 7 days compared to 24 hours post-injury. There 
was no effect of genotype (p>0.05). (C) There was a significant increase 
(p<0.001) in the percentage area Iba-1-positive in 9-month-old injured mice 
compared to sham mice at both 24 hours and 7 days post-injury. There was 
also a significant increase (p<0.001) in injured mice at 7 days compared 
to 24 hours post-injury. There was no effect of genotype (p>0.05). Values 
represent mean ± standard error. * = significance p<0.001 for injured vs sham. 
+ = significance p<0.001 for injured mice at 24 hours vs 7 days post-injury. 
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3.3.7 Astrocytic response 
The response of astrocytes to focal cortical brain injury was assessed using the 
GFAP antibody in both 3- and 9-month-old mice. The sham treatment did not 
induce any observable astrocytic response at either 24 hours or 7 days post-injury 
(Figure 3.7A). As expected, activated astrocytes were present near MOAB-2 
positive plaques in both sham and injured 9-month old APP/PS1 mice (Figure 
3.7A). The percentage areas occupied by GFAP-positive astrocytes are presented 
in Table 3.3. There was a significant main effect of treatment [F(1,46) = 55.29, 
p<0.001, partial η2 = 0.55] with an increase in the percentage area occupied by 
GFAP-positive astrocytes in injured compared to sham mice (Figures 3.7A, B 
and C). There was also a significant main effect of post-treatment time [F(1,46) 
= 35.18, p<0.001, partial η2 = 0.43] with an increase in the percentage area 
occupied by GFAP-positive astrocytes at 7 days post-injury compared to 24 
hours post-injury Figures 3.7A, B and C). A significant treatment×time 
interaction was also detected [F(1,35) = 130.33, p<0.001, partial η2 = 0.79] with 
the percentage area occupied by GFAP-positive astrocytes higher at 7 days post-
injury compared to 24 hours post-injury, in injured but not sham mice (Figures 
3.7A, B and C). There were no significant main effects or interactions for 
genotype or age (p>0.05) (Figures 3.7A, B and C). 
  
Figure 3.7 APP/PS1 mice have the same astrocytic response to focal brain 
injury as WT mice. (A) Representative sections labelled with GFAP for 
astrocytes. At 24 hours post-injury astrocytes surrounding the injury site have 
an activated phenotype. Activated astrocytes can also be seen surrounding 
plaques in 9-month old APP/PS1 mice. By 7 days post-injury a large 
accumulation of activated astrocytes can be seen at the injury site. Scale bar 
= 200μm. (B) There was a significant increase (p<0.001) in the percentage 
area GFAP-positive in 3-month-old injured mice compared to sham mice at 
both 24 hours and 7 days post-injury. There was also a significant increase 
(p<0.001) in injured mice at 7 days compared to 24 hours post-injury. There 
was no effect of genotype (p>0.05). (C) There was a significant increase 
(p<0.001) in the percentage area GFAP-positive in 9-month-old injured mice 
compared to sham mice at both 24 hours and 7 days post-injury. There was 
also a significant increase (p<0.001) in injured mice at 7 days compared to 24 
hours post-injury. There was no effect of genotype (p>0.05). Values represent 
mean ± standard error. * = significance p<0.001 for injured vs sham. + = 
significance p<0.001 for injured mice at 24 hours vs 7 days post-injury. 
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Table 3.3 Percentage of area covered by GFAP-positive astrocytes (means ± 
SEM) 
Genotype Treatment Age Time Area (%) 
 
APP/PS1 
 
Injury 3 months 24 hours 
7 days 
2.71 ± 0.49 
23.61 ± 3.14 
9 months 24 hours 
7 days 
5.16 ± 2.81 
23.37 ± 3.15 
Sham 3 months 24 hours 
7 days 
0.62 ± 0.09 
0.86 ± 0.39 
 9 months 24 hours 
7 days 
4.20 ± 1.73 
4.34 ± 1.34 
WT 
Injury 3 months 24 hours 
7 days 
3.68 ± 0.44 
24.47 ± 4.69 
9 months 24 hours 
7 days 
2.66 ± 0.06 
25.59 ± 1.05 
Sham 3 months 24 hours 
7 days 
0.31 ± 0.06 
0.61 ± 0.35 
 9 months 24 hours 
7 days 
1.08 ± 0.48 
0.50 ± 0.25 
 
3.3.8 Synaptic Response 
The synaptic response to focal brain injury was investigated using an antibody to 
synaptophysin, which labels the majority of pre-synaptic terminals (Calhoun et 
al., 1996). This analysis was only undertaken in 9-month-old mice. The number 
of synaptic puncta per µm2 (synaptophysin density), the percentage area covered 
and the average size of puncta was calculated. Table 3.4 shows synaptophysin 
densities and percentage areas occupied by synaptophysin puncta.  
There was a significant main effect of treatment [F(1,51) = 7.69, p<0.01, partial 
η2 = 0.13] with decreased synaptophysin density in injured compared to sham 
treated mice (Figures 3.8A and B). There was also a significant main effect of 
time on synaptophysin density [F(1,51) = 6.90, p<0.05, partial η2 = 0.12] with 
lower densities at 24 hours post-injury compared to 7 days post-injury (Figures 
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3.7A and B). A significant treatment×time×distance interaction was observed 
[F(1,40) = 5.08, p<0.05, partial η2 = 0.11]. This interaction was due to a 
significant reduction in synaptophysin density at 24 hours post-injury near the 
site in injured but not sham mice (Figures 3.8A and B). There was no main effect 
of either genotype or distance on synaptophysin density (p>0.05) (Figures 3.8A 
and B).  
 
Similarly, when looking at the percentage area covered by synaptophysin-
positive puncta, there was a significant main effect of treatment [F(1,51) = 5.23, 
p<0.05, partial η2 = 0.09] with a reduction in injured compared to sham treated 
mice (Figures 3.8A and C). There was also a significant main effect of time 
[F(1,51) = 6.72, p<0.05, partial η2 = 0.12] with an increase in the percentage area 
covered by synaptophysin-positive puncta at 7 days post-injury compared to 24 
hours post-injury (Figures 3.8A and C). A significant [F(1,51) = 5.41, p<0.05, 
partial η2 = 0.10] distance-related reduction in percentage area was also observed 
for sites near versus sites distant (Figures 3.8A and C). A significant 
treatment×time×distance interaction was also detected [F(1,40) = 4.63, p<0.05, 
partial η2 = 0.10] due to a significant reduction in the percentage area covered by 
synaptophysin-positive puncta at 24 hours post-injury near the site in injured but 
not sham mice. There was no significant main effect of genotype on this 
response (p>0.05) (Figures 3.8A and C).  
 
The average size of synaptophysin puncta was also measured. There was no 
significant main effects of treatment, post-treatment time or distance from the 
injury site (p>0.05). However, there was a significant main effect of genotype 
[F(1,51) = 8.96, p<0.01, partial η2 = 0.15] with APP/PS1 mice having smaller 
puncta than WT mice (0.39 ± 0.004 vs 0.41 ± 0.003, data not shown). A full 
factorial analysis showed no significant interactions with treatment (p>0.05), 
post-treatment time (p>0.05) or distance from the injury site (p>0.05). 
  
Figure 3.8 Focal brain injury reduces synaptophysin-postive synapses near the 
injury site at 24 hours post-injury. (A) Representative sections labelled with the 
presynaptic marker synaptophysin (green) and DAPI (blue) to label nuclei. The 
injury site was 60 μm from the edge of the image marked by the yellow *. Scale 
Bar = 20μm. (B) There was a significant reduction (p<0.05) in synaptophysin 
density near (60 μm from the injury site) at 24 hours post-injury compared to 
distant (120 μm from the injury site) and sham sites. (C)  There was a significant 
reduction (p<0.05) in the percentage area occupied by synaptophysin puncta 
near (60 μm from the injury site) at 24 hours post-injury compared to 
distant (120 μm from the injury site) and  sham sites. Bars represent mean ± 
standard error. * = significance p<0.05 for 24 hours near vs distant and sham. 
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Table 3.4 Synaptophysin density and percentage of area covered by 
synaptophysin-positive puncta (means ± SEM) 
Genotype Treatment Distance Time Density % Area 
 
APP/PS1 
 
Injury Near 24 hours 
7 days 
0.073 ± 0.011  
0.100 ± 0.006  
2.72 ± 0.27 
3.92 ± 0.41 
Distant 24 hours 
7 days 
0.102 ± 0.009  
0.114 ± 0.003  
4.03 ± 0.20 
4.34 ± 0.32 
Sham Near 24 hours 
7 days 
0.111 ± 0.006 
0.107 ± 0.005 
4.35 ± 0.24 
4.16 ± 0.23 
 Distant 24 hours 
7 days 
0.111 ± 0.004 
0.104 ± 0.004  
4.47 ± 0.28 
4.14 ± 0.37 
WT 
Injury Near 24 hours 
7 days 
0.064 ± 0.007 
0.100 ± 0.005 
2.51 ± 0.39 
4.19 ± 0.17 
Distant 24 hours 
7 days 
0.106 ± 0.007 
0.102 ±0.010 
4.32 ± 0.23 
4.46 ± 0. 27 
Sham Near 24 hours 
7 days 
0.105 ± 0.005  
0.114 ± 0.003  
4.21 ± 0.51 
4.51 ± 0.36 
 Distant 24 hours 
7 days 
0.095 ± 0.009  
0.108 ±0.005 
3.89 ± 0.40 
4.39 ± 0.24 
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3.4 Discussion 
 
TBI has been proposed to be a risk factor for the development of AD (Mortimer 
et al., 1991, Nemetz et al., 1999, Guo et al., 2000, Plassman et al., 2000, 
Fleminger et al., 2003), but the mechanisms underlying this relationship remain 
to be elucidated. The current study sought to examine the effects of focal brain 
injury on Aβ deposition, as well as the microglial and astrocytic responses and 
synaptic changes in the APP/PS1 mouse model of AD relative to WT mice. 
 
Several studies have investigated Aβ after experimental brain injury in transgenic 
AD mice, reporting both increased and decreased plaque loads (Nakagawa et al., 
1999, Nakagawa et al., 2000, Uryu et al., 2002). However, this and other studies 
(Smith et al., 1998, Tran et al., 2011a, Tran et al., 2011b) show no evidence of 
injury-induced changes in Aβ plaque dynamics. These data demonstrate that 
focal brain injury does not acutely induce Aβ plaque deposition in the 
somatosensory cortex of pre-plaque APP/PS1 mice, or acutely promote 
deposition after the onset of amyloidosis in older animals.  The wide range of 
reported effects of TBI on Aβ might be attributable to the type and severity of 
the experimental brain injury used; the injury used in this study was focal and 
affected only the neocortex. This allowed the examination of local plaque 
dynamics without the introduction of confounding variables such as large 
cortical tissue loss, widespread inflammation or DAI to the white matter tracts. 
The choice of time points may also have influenced the outcomes: past studies 
demonstrated more chronic changes in plaque deposition between 2- and 8-
months post-injury (Nakagawa et al., 1999, Nakagawa et al., 2000, Uryu et al., 
2002). Although Aβ plaques accumulate within hours following human TBI 
(Ikonomovic et al., 2004), it is possible that, in mouse models of AD, amyloid 
deposition is a slower process following brain injury. However, in vivo 
multiphoton microscopy in APP/PS1 mice has demonstrated that Aβ plaques can 
form in as quickly as 24 hours (Meyer-Luehmann et al., 2008). 
 
In the wake of TBI, activated microglia might plausibly reduce Aβ plaque load 
by phagocytosing plaques (Simard et al., 2006), although microglia have also 
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been implicated in plaque formation (Wegiel et al., 2000, reviewed in Nagele et 
al., 2004). Additionally, microglia have been shown to be detrimental following 
TBI (Reviewed in Kumar and Loane, 2012) and in AD (Reviewed in Streit, 
2004b) due to the release of pro-inflammatory cytokines. The findings of the 
current study suggest that the microglial/macrophage response stimulated by 
localized brain injury neither acutely induces nor reduces Aβ plaques: no change 
in plaque load was observed despite an evident microglial/macrophage response. 
This study also demonstrated that the microglial/macrophage response to brain 
injury in 9-month-old APP/PS1 mice is comparable to WT mice and 3-month-
old pre-plaque APP/PS1 mice. Thus, despite the presence of Aβ plaque-related 
microglia activation and neurodegeneration, the microglial/macrophage response 
to focal brain injury is not augmented on this background of neuroinflammation.  
 
Similar to microglia, astrocytes are implicated in both the degradation of Aβ 
plaques (Funato et al., 1998, Wyss-Coray et al., 2003b) as well as in contributing 
to the pathogenesis of AD (Pike et al., 1995, Reviewed in Verkhratsky et al., 
2010).  However, the findings of the current study demonstrate the astrocytic 
response elicited by focal brain injury did not cause any acute changes to Aβ 
plaque deposition. Additionally, the astrocytic response to brain injury, like the 
microglial/macrophage response, was the same in all groups, indicating that AD-
associated astrocytic changes do not impair the response to focal brain injury. 
 
APP accumulation is a well characterized marker of axonal injury in TBI 
(Gentleman et al., 1993, Otsuka et al., 1991), but there is some uncertainty about 
whether Aβ accumulates intra-neuronally and intra-axonally. Unlike many other 
commonly used antibodies for Aβ such as 6E10 (Youmans et al., 2012a), the 
antibody used for the current study, MOAB-2, does not cross-react with APP 
(Youmans et al., 2012a). The current study found no intra-neuronal or intra-
axonal Aβ in either APP/PS1 or WT mice after injury, in contrast to previous 
studies demonstrating acute accumulation of Aβ in white matter axons following 
CCI in the 3×Tg-AD (APPSWE, MAPTP301L, PSEN1M146V) and APP/PS1 mouse 
models of AD (Tran et al., 2011a, Tran et al., 2011b). It is possible that white 
matter axons accumulate Aβ only after either a more substantial injury and/or in 
relation to shear-forces present in CCI models.  
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This model of focal brain injury causes a highly reproducible, discrete lesion to 
the cortex with minimal tissue loss (King et al., 2001, Blizzard et al., 2011). 
Furthermore, substantial tissue remodeling occurs within 7 days post-injury (this 
study and Blizzard et al., 2013). The current results demonstrate that despite a 
significant acute loss of synaptophysin immunoreactivity near the injury site, by 
7 days post-injury, synaptophysin-positive puncta density was restored to 
baseline levels in both APP/PS1 and WT mice. This indicates that the mouse 
brain possessed a significant capability to recover lost synaptophysin 
immunoreactivity following injury, although the functional significance of this 
recovery is unknown. Further experiments using combinations of antibodies 
against synaptic proteins are required to determine the significance of this result.  
 
If the change in synaptophysin immunoreactivity is due to a loss and recovery of 
synapses, this data suggests an equal capacity for the recovery of synapses 
following injury despite the presence of AD-related neuropathology that causes 
local and remote loss of synapses in the APP/PS1 model at 12-months of age 
(Mitew et al., 2013a). With respect to the latter study, this also suggests that the 
synapse loss in APP/PS1 mice occurs via highly specific mechanisms. 
 
Two limitations must be taken into account when interpreting the results of this 
chapter. First, this model of focal cortical brain injury is not a clinical 
representation of most human brain injuries. However, it is a well characterized 
model (King et al., 2001, Chung et al., 2003, Chung et al., 2004, Chung et al., 
2007, Chung et al., 2008, Blizzard et al., 2011, Blizzard et al., 2013) that 
produces a well delineated injury in which the effect of the injury on nearby 
plaques could be easily quantified. Second, this study utilized the APP/PS1 
transgenic mouse model of AD amyloidosis, which harbors two mutations 
implicated in familial AD. Whilst most human TBI cases are not genetically 
predisposed to AD, such mutations are necessary in mice to produce Aβ plaques 
as WT rodents do not form plaques with aging (Selkoe, 1989) or after TBI 
(Pierce et al., 1996, Bramlett et al., 1997, Murai et al., 1998).  
 
Chapter 3 – Results 
	 62	
In conclusion, this study demonstrates that focal cortical brain injury does not 
accelerate the onset or progression of Aβ plaque deposition acutely in APP/PS1 
mice. Furthermore, it shows that APP/PS1 mice with established amyloidosis 
have normal microglial, astrocytic and synaptic responses to focal brain injury 
despite existing AD-like neuropathology. It remains to be seen however, whether 
a clinically relevant model of diffuse brain injury with a more widespread 
distribution of secondary pathology might alter Aβ plaque deposition after 
injury. 
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4 The effect of diffuse brain injury on Aβ dynamics in APP/PS1 
mice  
 
4.1 Introduction 
The previous chapter demonstrated that focal cortical damage does not alter Aβ 
plaque dynamics in APP/PS1 mice. However, the focal model of brain injury 
used causes structural brain damage to a very localized region of the cortex and 
does not damage underlying subcortical structures or cause extensive secondary 
pathology (Blizzard et al., 2011, King et al., 2001). Previous studies using the 
CCI model of experimental brain injury, which induces widespread brain damage 
and DAI to underlying white matter tracts (Xiong et al., 2013), have shown 
changes in Aβ plaque deposition post-injury (Nakagawa et al., 1999, Nakagawa 
et al., 2000, Uryu et al., 2002). Hence, widespread or diffuse injury may be 
required for TBI-induced alteration in Aβ plaque deposition.  
 
TBI-induced DAI causes impaired axonal transport and the formation of axonal 
swellings (Hanell et al., 2014, Tang-Schomer et al., 2012, Tang-Schomer et al., 
2010). Impaired axonal transport may be a primary event in the formation of Aβ 
plaques (Stokin et al., 2005), suggesting that DAI may be an important factor in 
the development of AD following TBI. 
 
The LFPI model is a clinically relevant, and highly reproducible, model of TBI 
that causes both focal and diffuse injury (Xiong et al., 2013, Alder et al., 2011). 
Unlike the CCI model, which causes widespread cortical damage and cortical 
loss (Lighthall, 1988, Smith et al., 1995), at a mild severity, LFPI does not cause 
cortical loss (Hylin et al., 2013), and hence allows the quantification of Aβ 
plaque load in the underlying injured cortical tissue.  
 
Thus far, the LFPI model has not been used to assess Aβ plaque dynamics after 
injury in transgenic AD mice. Therefore, the current study sought to investigate 
the acute and chronic effects of LFPI on Aβ dynamics in the APP/PS1 mouse 
model of AD. Previous CCI studies on the effect of TBI on Aβ plaque dynamics 
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in transgenic AD mouse models are heterogeneous in their experimental design. 
This makes comparing earlier studies difficult, and consequently the effect of 
TBI on Aβ plaque dynamics remains unclear. One experimental factor that has 
differed between various studies is the stage of amyloidosis present in transgenic 
mouse model at the time of injury. Thus, this chapter aimed to investigate the 
effect of diffuse TBI on Aβ plaque load in the APP/PS1 mouse at two different 
stages of amyloidosis, 30 days after injury. Furthermore, as astrocytes and 
microglial cells have been implicated in both the formation (Nagele et al., 2004, 
Pike et al., 1995, Verkhratsky et al., 2010, Wegiel et al., 2000) and clearance 
(Funato et al., 1998, Liu et al., 2010, Paresce et al., 1996, Simard et al., 2006, 
Wyss-Coray et al., 2003a) of Aβ plaques, this chapter also assesses the glial 
response to LFPI in APP/PS1 mice. To this end, 3-month-old pre-plaque mice 
and 6-month-old plaque accumulating mice were subjected to mild LFPI. 
Immunohistochemical methods were used to assess changes in Aβ plaque 
deposition as well as astrocytes and microglia post-injury.  
  
Chapter 4 – Results 
	 65	
4.2 Materials and Methods 	
4.2.1 Mice 
All experimental procedures utilized male APPSWE/PSENdE9 (APP/PS1) 
(Jankowsky et al., 2001) and C57BL/6 wild-type (WT) littermate control mice at 
either 3- or 6-months of age.  
 
4.2.2 Genotyping 
Genotyping was performed as outlined in the Material and Methods section 2.2 
using the primers specified in Chapter 3 section 3.2.2. Primers and expected PCR 
product sizes are as specified in Chapter 3 Table 3.1.  
 
4.2.3 In vivo model of diffuse traumatic brain injury 
In vivo diffuse traumatic brain injury was performed as outlined in the Materials 
and Methods section 2.4. For the 24 hours time-point, 3-month-old APP/PS1 and 
C57/Bl6 WT mice were used (n=3-4 mice per group, total n=14). For the 30 day 
time point, 3- and 6-month old APP/PS1 mice (n=5 mice per age and treatment, 
total=20) were used. A cohort of 6-month-old C57/Bl6 mice (n=5 per treatment, 
total=10) were also used to determine if LFPI caused plaque deposition in WT 
animals and if their response to injury differed to mice with established plaque 
pathology. Three- and 6-month-old mice were perfused at 30 days post-injury 
making them 4- and 7-months-old at analysis, respectively. 	
4.2.4 Tissue preparation 
At either 24 hours or 30 days post-injury, mice were terminally anesthetised and 
transcardially perfused as per the Materials and Methods section 2.5. Serial 50um 
coronal sections were cut on a vibratome (Leica VT1000). For total Aβ labelling 
the MOAB-2 antibody was used following formic acid antigen retrieval as 
described in Materials and Methods section 2.6.2. Immunohistochemistry was 
then performed. 
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4.2.5 Immunohistochemistry 
Immunohistochemistry was performed as described in the Materials and Methods 
section 2.6. Thioflavin-S staining for fibrillar Aβ deposits and immunolabelling 
with the following antibodies was performed: MOAB-2 for Aβ deposits, APP, 
Iba-1 for microglia, GFAP for astrocytes, AT8 for hyperphosphorylated tau and 
SMI-312 for axons and SMI-32 for neuronal cell bodies, dendrites and thick 
axons (refer to Table 2.1 in the Materials and Methods section for antibody 
information).  
 
4.2.6 Confocal microscopy and quantitation 
Confocal microscopy was performed on a Perkin-Elmer Ultraview VOX 
confocal imaging system using Volocity 6.3 software for image capture and 
stitching (10% overlap, no corrections). MOAB-2 and thioflavin-S were imaged 
using a 10x objective and GFAP and Iba-1 with a 20x objective. MOAB-2 and 
thioflavin-S plaque loads (percentage area positive) were calculated 
independently for each hemisphere, from the midline to the rhinal fissure. Four 
sections per mouse, for both MOAB-2 and thioflavin-S were used spanning the 
cortex from bregma +0.5mm to −2.5mm. This region was chosen for analysis 
after visual survey of APP- and Aβ-labelled axonal and neuronal pathology 
across the whole brain at 24 hours after LFPI. Iba-1 and GFAP analyses were 
performed on 2 sections per mouse, per marker in the same regions used for 
plaque analyses. Glial markers were quantified across a wedge shaped area 
spanning 1.5mm across the ipsilateral cortex, beginning at the cingulum. And 
centered beneath the injury site. The markers were quantified as a percentage of 
area covered by labelled cells. Images were processed to 8-bit greyscale and 
segmented using ImageJ 1.48r (NIH; Schneider et al., 2012). Segmentation was 
performed using custom plug-ins written in Java, including an automated random 
forest classifier (Samaroo et al., 2012, Sommer et al., 2011). The custom random 
forest classifier was developed using data generated for this thesis by O’Mara 
and Kirkcaldie (Manuscript in preparation). Briefly, this required an independent 
image classifier for each antibody or marker (ie. MOAB-2, thioflavin-S, GFAP 
and Iba-1). These classifiers were trained using manual annotation of ‘labelling’ 
and ‘background’ in a representative set of example images, from which the 
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random forest classifier optimised its automated image segmentation rules. The 
separate classifiers were then used for their respective labels to segment the 
pixels of the original images into label and background classes. An image mask 
of the region of interest was then applied to the segmented images, after which 
ImageJ Particle Analysis tool was used to quantify the percentage area of 
labelling. Analysis was performed on the stitched images acquired on the Perkin-
Elmer Ultraview VOX confocal imaging system using Volocity 6.3 software for 
image capture and stitching (10% overlap, no corrections). The stitched images 
had a grid-like pattern due uneven illumination across the field of view. The 
orientation of the mounted sections was the same for all samples and thus the 
orientation of the grid pattern was also the same for all samples. This grid-like 
pattern did not influence the results due to the use of the random forest classifier 
for segmentation. The random forest segmenter was created by supervised 
machine learning, using images with the same grid pattern. The classifier 
calculates a range of image derivatives as inputs to the segmentation process thus 
using local image context (eg texture, edges) to evaluate each pixel. Therefore, 
intensity shifts (as seen in the grid-like pattern) do not impact the segmentation 
(Sommer et al., 2011). See Appendix B for an example of an original image and 
its segmentation using the random forest segmenter.  
 
4.2.7 Statistical analysis 
IBM SPSS statistics (Version 19) was used for all statistical analyses and graphs 
were made using GraphPad Prism (Version 6.0c). The MOAB-2 and thioflavin-S 
data were analysed using a two-way analysis of variance (ANOVA) model for 
the main effects of the factor variables: treatment (LFPI and sham) and 
hemisphere (ipsilateral and contralateral to the LFPI/sham site), and then a full 
factorial ANOVA was used to test for interactions between the variables. For the 
GFAP and Iba-1 data ANOVA methods were also used. The 3-month-old and 6-
month-old cohorts were analysed separately. For the 3-month-old cohort, 
Student’s t-test was used for the factor variable treatment (LFPI or sham). The 6-
month-old cohort had both APP/PS1 mice and WT mice and thus a two-way 
ANOVA was performed for the main effects of the factor variables treatment 
(LFPI or sham) and genotype (APP/PS1 and WT) and the interaction effect 
Chapter 4 – Results 
	 68	
between these two variables. All data are expressed as means ± standard error of 
the mean (SEM) with significance set at p < 0.05 and estimates of effect size (eta 
squared) reported for significant effects.  
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4.3 Results 	
4.3.1 Characterisation of the LFPI model 
A fluid pressure pulse of 1.25-1.35atm (Figure 4.1A) was delivered to the intact 
dura and, thus, this LFPI was considered of mild severity (Alder et al., 2011). 
The average pressure for each of the injury groups was 1.28±0.02 for 3 month 
APP/PS1 mice, 1.27±0.05 for 6 month APP/PS1 mice and 1.25±0.01 for 6 month 
WT animals and was not significantly different between the groups (p>0.05) 
(Figure 4.1B). This injury did not induce prolonged unconsciousness, with the 
animals able to right themselves immediately following the injury.   
 
Following LFPI, the dura remained intact. There was no overt cavitation or 
hemorrhage at either 24 hours or 30 days post-injury.  At the macroscopic level, 
the brains of injured and sham mice were indistinguishable. 
 
4.3.2 Diffuse axonal injury and amyloid beta accumulation at 24 hours post-
LFPI 
Three-month-old APP/PS1 mice were used to examine the pattern of DAI 
produced by LFPI acutely after injury and to confirm previous finding of intra-
neuronal and intra-axonal Aβ accumulation in APP/PS1 mice. APP 
immunohistochemistry was used to assess axonal pathology following LFPI, as it 
is a well-described pathological hallmark of DAI (Gentleman et al., 1993, Otsuka 
et al., 1991, Sherriff et al., 1994). Intra-neuronal and intra-axonal Aβ 
accumulation was assessed using the MOAB-2 antibody. The presence of intra-
neuronal labelling was determined by cellular morphology.  
 
At 24 hours post-injury, APP labelling accumulated in neuronal processes within 
the cortex, white matter tracts and hippocampus in APP/PS1 and WT mice 
(Figure 4.2). In the cortex, APP was present in cell bodies, injured neuronal 
processes extending from cell bodies, axonal varicosities resembling ‘beads on a 
string’ and axonal bulbs. In the white matter tracts and hippocampus, APP 
labelling was present in axonal varicosities resembling a ‘beads on a string’  
Figure 4.1 Average injury severity as determined by the fluid pressure pulse 
delivered did not vary between groups. (A) Representative pressure trace 
recorded during a LFPI. The trigger point refers to the point at which the 
pendulum of the device moves past the sensor point  on the device. (B) The 
was no signficant difference (p>0.05) in the average pressure pulse delivered 
between any of the injured groups. Bars represent means ± standard error.
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morphology. The amount of APP-labeled axonal pathology did not appear to 
differ between APP/PS1 or WT mice. This pathology was not seen in sham 
treated APP/PS1 or WT mice.  
 
In injured APP/PS1 mice, MOAB-2 labeled Aβ was specifically localised  within 
neurons in the cortex, white matter tracts and the hippocampus (Figure 4.2). This 
labelling was typically co-localised with APP labelling, however, it appeared less 
abundant. In the cortex, Aβ labelling was present in the cell bodies, injured 
neuronal processes, axonal varicosities and axonal end bulbs. It was also 
observed in axonal varicosities in the white matter tracts and the hippocampus. 
Aβ labelling was observed to be less abundant than APP labelling and appeared 
primarily in larger axonal varicosities and in axonal bulbs. No intraneuronal or 
intra-axonal Aβ accumulations were present in either injured or sham WT mice 
or sham injured APP/PS1 mice (Figure 4.2). 
 
4.3.3 Plaque load in 3-month-old APP/PS1 mice 30 days post-LFPI             
(4-months-old at pathological analysis) 
This study sought to investigate the chronic effects of LFPI on the onset of 
plaque deposition in 3-month-old pre-plaque APP/PS1 mice. APP/PS1 mice 
were subjected to LFPI or sham treatment and perfused at 30 days post-injury (4-
months-old). The MOAB-2 antibody was used to label all Aβ and the stain 
thioflavin-S was used to label fibrillar plaques. No intra-neuronal Aβ labeling 
was detected in LFPI or sham treated 3-month-old APP/PS1 mice at 30 days 
post-injury. Very few Aβ plaques were detected in sham treated APP/PS1 mice 
at 30 days post-injury (Figures 4.3A, 4.4A) as has been previously reported for 
this age (Garcia-Alloza et al., 2006). However, at 30 days post-LFPI, thioflavin-
S-labeled and numerous MOAB-2-labeled Aβ plaques were present in APP/PS1 
mice (Figures 4.3A, 4.4A). 
 
At 30 days post-injury, ANOVA demonstrated there was a significant main 
effect of treatment, with LFPI increasing the MOAB-2-labelled Aβ plaque load 
compared to sham treatment (0.29 ± 0.02% vs 0.12 ± 0.01% in both 
hemispheres, [F(1,17) = 50.1, p<0.001, partial η2 0.75], Figure 4.3B). Likewise,  
Figure 4.2 LFPI causes diffuse axonal injury and the intra-neuronal 
accumulation of Ab in APP/PS1 mice at 24 hours post-injury. APP and Ab 
immunohistochemistry in 3-month-old APP/PS1 and WT mice. Scale bar = 
50mm. APP accumulations can be seen within axonal swellings and bulbs as 
well as in neuronal cell bodies in both APP/PS1 and WT mice. Ab labelling is 
seen within neuronal cell bodies and axonal swellings and bulbs in APP/PS1 
mice only, but not WT mice. APP and Ab labelling co-localise (yellow arrows), 
however Ab labelling appears less abundant than APP labelling.
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there was also a significant main effect of treatment on thioflavin-S plaque load 
in injured compared to sham mice (0.055% ± 0.006 vs 0.022 ± 0.003% in both 
hemispheres, [F(1,17) = 27.8, p<0.001, partial η2 0.62], Figure 4.4B). For both 
MOAB-2 labelling and thioflavin-S staining, there was no significant main effect 
of hemisphere (p > 0.05) and there was no treatment x hemisphere interaction (p 
> 0.05). Therefore, LFPI caused a significant increase in the MOAB-2-labelled 
Aβ and thioflavin-S-labelled fibrillar plaque load in both cortical hemispheres at 
30 days post-injury. Table 4.1 gives the means ± the SEM for ipsilateral and 
contralateral hemispheres.  
  
4.3.4 Plaque load in 6-month-old APP/PS1 mice 30 days post-LFPI             
(7-months-old at pathological analysis) 
Aβ plaques deposition begins at 4 months of age in APP/PS1 mice and by 7 
months of age, numerous Aβ plaques labelled with Aβ antibodies and thioflavin-
S are usually present (Garcia-Alloza et al., 2006). Thus, 6-month-old APP/PS1 
mice were subjected to LFPI and examined at 30 days post-injury (at 7 months of 
age) to assess the effects of TBI on the progression of Aβ plaque deposition. 
  
No intra-neuronal Aβ labeling was observed in LFPI or sham treated mice at 30 
days post-injury. Sham treated APP/PS1 mice had numerous MOAB-2 and 
thioflavin-S labelled Aβ plaques (Figures 4.3A and 4.4A), as expected for this 
age (Garcia-Alloza et al., 2006). LFPI treated mice had substantially fewer 
MOAB-2 labelled Aβ plaques, but a similar amount of thioflavin-S labelled 
fibrillar Aβ plaques compared to sham treated mice (Figures 4.3A and 4.4A).  
 
ANOVA demonstrated a main effect of treatment for MOAB-2 with LFPI 
significantly decreasing the MOAB-2-labelled Aβ plaque load compared to sham 
treatment (2.02 ± 0.16% vs 3.04 ± 0.27%, both hemispheres, [F(1,17) = 10.5, 
p<0.01, partial η2 0.38], Figure 4.3B). There was no significant main effect of 
hemisphere (p>0.05) and there was no treatment x hemisphere interaction 
(p>0.05) for MOAB-2-labelled Aβ plaque load. For thioflavin-S staining of 
plaques, there was no significant main effect of treatment (0.15 ± 0.02% vs 0.20 
± 0.02% both hemispheres, p> 0.05, Figure 4.4B) or hemisphere (p> 0.05) and 
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there was no significant treatment x hemisphere interaction (p> 0.05). Thus, 
LFPI caused a significant decrease in MOAB-2-labelled Aβ plaque load in both 
cortical hemispheres of the brain, however, did not significantly alter thioflavin-
S-labelled fibrillar plaque load.  Table 4.1 gives the means ± the SEM for 
ipsilateral and contralateral hemispheres. 
 
Table 4.1 MOAB-2 and thioflavin-S plaque loads (means ± SEM). 
Group 
MOAB-2 plaque load (%) Thioflavin-S plaque load (%) 
Ipsilateral Contralateral Bilaterally Ipsilateral Contralateral Bilaterally 
3m LFPI 0.32 ± 0.03 0.26 ± 0.03 0.29 ± 0.02 0.062 ± 0.006 0.047 ± 0.009 0.055 ± 0.006 
3m Sham 0.13 ± 0.02 0.12 ± 0.02 0.12 ± 0.01 0.022 ± 0.004 0.022 ± 0.005 0.022 ± 0.003 
6m LFPI 1.98 ± 0.27 2.06 ± 0.18 2.02 ± 0.16 0.16 ± 0.02 0.15 ± 0.04 0.15 ± 0.02 
6m Sham 0.16 ± 0.02 0.15 ± 0.04 3.04 ± 0.27 0.18 ± 0.01 0.22 ± 0.04 0.20 ± 0.02 
3m, 3 months; 6m, 6 months. 
4.3.5 Amyloid beta plaque dynamics in WT mice 30 days post-LFPI 
Six-month-old WT mice were also examined for Aβ plaque deposition using the 
MOAB-2 antibody and thioflavin-S staining following LFPI. As MOAB-2 is a 
pan-specific Aβ antibody, which labels both mouse and human Aβ, (Youmans et 
al., 2012a) it will also detect endogenous mouse Aβ accumulations after LFPI. 
No Aβ labelling with either MOAB-2 or thioflavin-S was observed in WT mice 
at 30 days post-injury (Figure 4.5).  
 
4.3.6 Astrocytic response at 30 days post-LFPI  
The astrocytic response to LFPI was examined using an antibody to GFAP. 
Activated astrocytes surrounded Aβ plaques in APP/PS1 mice in both age 
cohorts (Figure 4.6A). For the 3-month-old cohort, there was no significant 
difference in the percent area occupied by GFAP labelling between injured and 
sham APP/PS1 mice at 30 days post-injury (p>0.05, Figure 4.6B). For the 6-
month-old cohort at 30 days after LFPI, there was no main effect of treatment 
(p>0.05) or genotype (Figure 4.6B, p>0.05) on the percent area GFAP-positive. 
Thus, at 30 days post-injury, there was no difference in the percent area of 
GFAP-labelled astrocytes in injured mice compared to sham treated mice in any 
group. Table 4.2 summarises the means ± SEM for each group analysed.  
Figure 4.3 LFPI effects total Ab plaque load in APP/PS1 mice at 30 days 
post-injury. (A) Ab immunohistochemistry with the MOAB-2 antibody. 
Right side is ipsilateral to the injury or sham site. Scale bar=1000mm. 
(B) There was a significant increase in total Ab plaque load (p<0.001) in 
injured compared to sham 3-month-old APP/PS1 mice. (C) There was a 
significant decrease in total Ab plaque load (p<0.01) in injured compared 
to sham 6-month-old APP/PS1 mice. Bars represent means ± standard error. 
*** denotes significance at p<0.001 for LFPI versus sham and ** denotes 
significance p<0.01 for LFPI versus sham. Ipsi = ipsilateral to the injury or 
sham site, Contra = contralateral to the injury or sham site.
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Figure 4.4 Fibrillar Ab plaque load is effected by LFPI in 3- but not 6-month-
old APP/PS1 mice at 30 days post-injury. (A) Representive sections stained 
with thioflavin-S for fibrillar Ab deposits. Right side is ipsilateral to the injury 
or sham site. Scale bar=1000mm. (B) LFPI caused a significant (p<0.001) 
increase in fibrillar Ab plaque load in 3-month-old APP/PS1 mice at 30 days 
post-injury. (C) LFPI did not significantly (p>0.05) effect fibrillar Ab plaque 
load in 6-month-old APP/PS1 mice at 30 days post-injury. Bars represent 
means ± standard error. *** denotes significance at p<0.001 for LFPI versus 
sham. Ipsi = ipsilateral to the injury or sham site, Contra = contralateral to 
the injury or sham site.
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Figure 4.5 LFPI does not cause Ab plaque deposition in WT mice at 30 
days post-injury. Ab immunohistochemistry with the MOAB-2 antibody and 
thioflavin-S staining in injured and sham WT mice. Scale bar=1000mm. 
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Table 4.2 Percentage area covered by GFAP labelled astrocytes, and Iba-1 
labelled microglia/macrophages. 
Group % area GFAP % area Iba-1 
3m APP/PS1 LFPI 28.3 ± 1.6 14.4 ± 1.0 
3m APP/PS1 Sham 23.9 ± 3.5 12.5 ± 0.7 
6m APP/PS1 LFPI 24.4 ± 3.0 15.5 ± 1.0 
6m APP/PS1 sham 27.9 ± 2.5 16.4 ± 1.2 
6m WT LFPI 24.2 ± 3.1 14.7 ± 1.3 
6m WT Sham 19.3 ± 0.6 14.6 ± 1.4 
3m, 3 months; 6m, 6 months. 
4.3.7 Microglial/macrophage response at 30 days post-LFPI  
The microglial/macrophage response to LFPI was examined using the Iba-1 
antibody. Microglia surrounded Aβ plaques in both 3- and 6-month-old injured 
and sham mice (Figure 4.7A). In the 3-month-old cohort, there was no significant 
difference in the percent area covered by Iba-1-labelled microglia/macrophages 
in sections from injured and sham APP/PS1 mice at 30 days post-injury (p>0.05, 
Figure 4.7B). In the 6-month-old cohort, 30 days after LFPI, there were no 
significant main effects of treatment (p>0.05) or genotype (p>0.05) on the 
percent area Iba-1-labelled (p>0.05, Figure 4.7B). There was also no treatment x 
genotype interaction (p>0.05) for the percent area Iba-1-labelled. Therefore, at 
30 days post-injury, there was no difference in the percent area of Iba-1-labelled 
microglia/macrophages in injured mice compared to sham treated mice or in 
APP/PS1 mice versus WT mice. Table 4.2 summarises the means ± SEM for 
each group analysed.  
 
4.3.8 Hyperphosphorylated tau at 30 days post-LFPI 
The AT8 antibody against hyperphosphorylated tau was used to examine 
misprocessing of tau following LFPI. As previously reported in other transgenic 
mouse models of AD (Woodhouse et al., 2009), AT8-immunoreactivity was 
detected within a small subgroup of dystrophic neurites surrounding Aβ plaques 
in APP/PS1 mice (see Figure 3.5). No AT8 labelling was detected within 
neurons anywhere else in the cortex at 30 days post-injury in any group of mice 
(Figure 4.8).  
Figure 4.6 There is no difference in the percent area of astrocytic labelling 
between injured and sham mice or APP/PS1 and WT mice at 30 days post-
injury. (A) GFAP immunolabelling in the ipsilateral cortex. Scale bar=500mm. 
(B) There were no significant differences (p<0.05) in the percent area of 
GFAP immunolabelling between injured and sham treated mice or APP/PS1 
and WT mice at 30 days post-injury. Bars represent means ± standard error.
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Figure 4.7 There is no difference in the percent area of microglial/macrophage 
labelling between injured and sham mice or APP/PS1 mice and WT mice 
at 30 days post-injury. (A) Iba-1 immunolabelling in the ipsilateral cortex. 
Scale bar=500mm. (B) There were no significant differences (p<0.05) in the 
percent area of Iba-1 immunolabelling between injured and sham treated 
mice or APP/PS1 and WT mice at 30 days post-injury. Bars represent means 
± standard error.
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Figure 4.8 LFPI does not induce hyperphosphorylated tau at 30 days post-
injury in APP/PS1 or WT mice. AT8 immunolabelling in the ipsilateral cortex. 
No immunolabelling was observed except in dystrophic neurites surrounding 
plaques (data not shown, see figure 3.5). Scale bar = 50μm.
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4.3.9 Neurofilament changes at 30 days post-LFPI 
Changes to neurites at 30 days after LFPI were examined by using the SMI-312 
and SMI-32 antibodies. SMI-312 is an antibody cocktail containing antibodies 
that bind to a variety of phosphorylated neurofilament epitopes, principally 
labelling axons, whereas SMI-32 labels a non-phosphorylated epitope on 
neurofilament H and, thus, visualizes neuronal cell bodies, dendrites and some 
axons (Sternberger and Sternberger, 1983, Goldstein et al., 1983). Besides Aβ 
plaque-associated dystrophic neurites, no neuritic pathology was visualized with 
these markers at 30 days post-injury in any group of mice (Figure 4.9). 
  
Figure 4.9 No neurofilament-positive neuritic pathology was observed 
at 30 days after LFPI in APP/PS1 or WT mice. SMI-312 and SMI-32 
immunolabelling in the ipsilateral cortex. No neuritic pathology was observed 
except dystrophic neurites surrounding plaques (data not shown). Scale bar = 
50μm.
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4.4 Discussion  
Understanding the pathological mechanism underlying the relationship between 
TBI and Aβ plaque deposition may lead to a better understanding of sporadic AD 
and direct the development of therapeutic interventions. The current study sought 
to investigate whether, and how, Aβ plaque dynamics are altered after LFPI as 
previous studies in transgenic models have reported conflicting results (Uryu et 
al., 2002, Nakagawa et al., 1999, Nakagawa et al., 2000, Smith et al., 1998, 
Collins et al., 2015). This study demonstrated both increased and decreased Aβ 
plaque deposition in APP/PS1 mice depending on the stage of Aβ deposition at 
the time of TBI. In 3-month-old pre-plaque APP/PS1 mice, injury accelerated 
total and fibrillar Aβ deposition in the cortex bilaterally after LFPI. However, in 
6-month-old APP/PS1 mice with established amyloidosis, LFPI resulted in a 
bilateral decrease in total, but not fibrillar, Aβ plaque load in the cortex after 
LFPI. Hence, this study indicates that the stage of amyloidosis in the transgenic 
AD mouse model at the time of TBI may be a factor in determining the response 
of the brain to injury, including subsequent Aβ dynamics.  
 
Comparisons between this and previous animal studies are difficult to make due 
to many differing experimental factors including: the time points analysed after 
injury, the AD transgenic mouse model used, the injury model and severity used 
and the area of the brain analysed for Aβ plaque deposition. The current data 
does, however, replicate many of the findings in previous literature. First, the 
current study supports the results of Uryu et al. (2002), which also show an 
increase in Aβ plaque load in AD transgenic mice injured prior to the 
development of amyloidosis. Second, in transgenic mice with established 
amyloidosis, our results support those of Nakagawa et al. (2000) showing a 
decrease in Aβ plaque load after injury. Third, as previously reported in 
numerous other studies, no plaques were observed in WT mice after TBI 
(Bramlett et al., 1997, Ciallella et al., 2002, Iwata et al., 2002, Masumura et al., 
2000, Pierce et al., 1996) indicating that, in these models, the human APP 
isoform, possibly requiring mutation and overexpression, is still a requirement 
for brain amyloidosis.  
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The finding of increased Aβ plaque load in APP/PS1 mice injured prior to plaque 
development also supports epidemiological data showing accelerated AD onset 
in genetically predisposed individuals with a history of TBI (Nemetz et al., 1999) 
as well as post-mortem human data showing plaque deposition following TBI 
(Chen et al., 2009, DeKosky et al., 2007, Ikonomovic et al., 2004, Johnson et al., 
2012, Nicoll et al., 1995, Roberts et al., 1991, Roberts et al., 1994, Smith et al., 
2003, Uryu et al., 2007). 
 
A potential mechanism for the increase in Aβ plaque deposition reported in the 
current study may be TBI-induced DAI. DAI is a significant pathology in TBI 
and is characterized by axonal swellings, which occur due to injury-induced 
damage to the axonal cytoskeleton, causing transport deficits and subsequent 
accumulation of cargoes (Tang-Schomer et al., 2012, Tang-Schomer et al., 
2010). APP undergoes fast axonal transport (Koo et al., 1990) and its 
accumulation after TBI is a pathological hallmark of DAI (Gentleman et al., 
1993, Otsuka et al., 1991, Sherriff et al., 1994). This study and other have shown 
the accumulation of APP’s cleavage product Aβ within diffusely injured axons 
after experimental TBI in transgenic AD mouse models (Abrahamson et al., 
2006, Tran et al., 2011a, Tran et al., 2011b) and in human TBI cases (Chen et al., 
2009, Smith et al., 2003, Uryu et al., 2007). Furthermore, a study of TBI in swine 
demonstrated injury-induced plaques in the white matter tracts of pigs with the 
most extensive axonal pathology (Smith et al., 1999).  
 
Further evidence for axonal transport deficits leading to Aβ plaque deposition 
comes from a study by Stokin et al. (2005) demonstrating that experimentally-
induced interruption of axonal transport by down-regulation of kinesin-I results 
in more axonal swellings and increased Aβ deposition in the brains of transgenic 
AD mice. Furthermore, the study also demonstrated axonal swellings, 
morphologically similar to those seen in axonal injury, in AD transgenic mouse 
models prior to Aβ plaque deposition and in areas of the human brain devoid of 
Aβ plaques in early AD (Stokin et al., 2005). Thus, interrupted axonal transport 
and intracellular accumulation of Aβ may be early pathogenic events in the 
development of plaques.  
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The release of Aβ from axonal swellings may occur by the normal route, which 
is endosome recycling to the cell surface (Yamazaki et al., 1996, Koo et al., 
1996, Koo and Squazzo, 1994) or by axonal disconnection or lysis. Intracellular 
Aβ42 accumulation is suggested to be neurotoxic to neurons (Kienlen-Campard 
et al., 2002), and thus following TBI may result in neuronal cell death, expulsion 
of Aβ and plaque formation. 
 
The increase in cortical Aβ plaque load reported in this study was bilateral, 
which may be explained by the commissural connections between the two 
cerebral hemispheres. Commissural axons projecting into both hemispheres 
would be injured within the white matter tracts by LFPI, and thus if axonal 
transport deficits cause increased Aβ deposition, both hemispheres would show 
increased plaque load.  
 
Alternatively, the bilateral changes in Aβ plaque load after TBI may be due to 
disruption in normal neuronal activity within the cortex. It has been shown 
previously that unilateral ablation of the olfactory epithelium and thus removal of 
peripheral sensory input, results in decreased Aβ plaque load in the olfactory 
bulb and cortex, bilaterally in APP/PS1 mice (Bibari et al., 2013). Similarly, 28 
days of unilateral vibrissae deprivation in APP/PS1 mice has been shown to 
reduce Aβ plaque growth and formation in the barrel cortex (Bero et al., 2011). 
Thus LFPI may have caused enhanced or reduced cortical neuronal activity, 
resulting in increased or decreased Aβ plaque deposition at 30 days post-injury. 
 
In contrast to the increase in Aβ plaque deposition observed in injured 3-month-
old mice, this study also demonstrated a significant reduction in cortical Aβ 
plaque load bilaterally in injured 6-month-old mice compared to their uninjured 
counterparts.  
 
A reduction in Aβ plaque load in brain-injured mice may potentially be due to 
either decreased deposition or increased clearance. A possible mechanism for 
increased Aβ plaque clearance after TBI is via increases in activated glia. The 
brain possesses two types of microglia, resident microglia and newly 
differentiated microglia derived from bone marrow stem cells (reviewed in 
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Soulet and Rivest, 2008). Following TBI, resident microglia become activated 
and migrate to the site of injury (Davalos et al., 2005). Similarly, neurological 
insults have been shown to induce the migration of bone marrow derived 
macrophages (BMDM) into the brain, which differentiate into microglia (Priller 
et al., 2001).   
 
In AD, activated microglia surround Aβ plaques (reviewed in Malm et al., 2015) 
and in transgenic AD mouse models, many of these cells have been demonstrated 
to be BMDM (Simard et al., 2006), which are chemoattracted to Aβ40/42, have a 
specific immune reaction to Aβ and possess the ability to phagocytose Aβ 
plaques (Simard et al., 2006). Depletion of BMDM results in increased Aβ 
plaque deposition in the APP/PS1 mouse model of AD (Simard et al., 2006) and 
local inflammation induced by lipopolysaccharide injections into the 
hippocampus increases the infiltration of these cells while decreasing the Aβ 
plaque burden (Malm et al., 2005). Thus, following TBI, phagocytic BMDM 
recruited into the brain due to injury-induced inflammation may phagocytose 
existing Aβ plaques leading to an overall reduction in plaque load in 6-month-old 
APP/PS1 mice. In plaque-free 3-month-old APP/PS1 mice, Aβ plaques are not 
present for the BMDMs to phagocytose. Instead these cells will only have the 
TBI-induced damage to responds to, where they have been shown to have both 
beneficial and detrimental effects (reviwed in Loane and Byrnes, 2010). 
Detrimental effects include inducing an inflammatory environment, which has 
been suggested to enhance Aβ plaque formation (reviewed in Streit, 2004a).  
 
Astrocytes like microglia and BMDM have also been shown to phagocytose Aβ 
(Funato et al., 1998, Wyss-Coray et al., 2003a), as well as be detrimental in AD 
due to the release of pro-inflammatory molecules (reviewed in Verkhratsky et al., 
2010). Both the microglial and astrocytic responses were measured at 30 days 
after injury and no differences in the percent area of immuno-labelling for either 
cell type was found. At this protracted time point, an earlier difference may not 
be apparent or the sample size may have been inadequate to detect a significant 
result. Thus, an analysis of the glial responses in APP/PS1 mice throughout the 
time course after TBI should be the focus of future studies. There may also have 
been morphological or phenotypical differences in the microglia or astrocytes of 
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injured mice compared to sham mice, or APP/PS1 mice compared to WT mice. 
This limitation should be addressed in future studies examining the morphology 
of glial cells, and assessing the contribution of BMDM to the glial response. One 
phenotypical difference in astrocytes that may affect Aβ dynamics after TBI is 
the expression of AQP4. AQP4 is an integral part of the glymphatic system and 
is expressed perivascularily on astrocytic endfeet where it plays an important role 
in the clearance of solutes, including Aβ (Iliff et al., 2012). However, following 
TBI, AQP4 expression mislocalises from the perivascular astrocytic endfeet to 
the soma (Ren et al., 2013). This may result in inefficient clearance of Aβ 
following TBI, and the development of plaques. Other clearance mechanisms 
that may be affected following TBI include changes in the expression and/or 
activity of neprilysin (Chen et al., 2009, Iwata et al., 2000, Johnson et al., 2009) 
and alterations to the newly discovered cerebral lymphatic system (Louveau et 
al., 2015), both of which warrant further investigation.  
 
As WT rodents do not form Aβ with aging (Selkoe, 1989) or after TBI (Bramlett 
et al., 1997, Ciallella et al., 2002, Iwata et al., 2002, Masumura et al., 2000, 
Pierce et al., 1996), the following study used the APP/PS1 mouse model of AD. 
This transgenic mouse model expresses two familial AD mutations and develops 
Aβ plaques at a young age (Jankowsky et al., 2001). As the majority of human 
TBI sufferers are not genetically predisposed to developing AD, this limitation 
must be taken into account when interpreting the results of this study. 
Furthermore, although the LFPI is a clinically relevant model, it does not 
recapitulate all of the features of human TBI (Xiong et al., 2013). For example 
the need for a craniotomy limits the formation of raised intracranial pressure 
(Albert-Weissenberger and Siren, 2010) following TBI and the effect of such 
factors on Aβ plaque deposition and tau hyperphosphorylation are unknown. 
Although the current study did not demonstrate tau hyperphosphorylation as 
reported in previous studies of TBI (Goldstein et al., 2012, Smith et al., 1999) it 
is possible that at more acute or chronic time points or using different 
phosphorylated-tau antibodies this pathology is present.  
 
In conclusion, this study demonstrated that experimental TBI in the APP/PS1 
mouse model of AD can modulate Aβ plaque deposition in the cortex bilaterally 
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at 30 days post-injury, but that the effect of injury is dependent on the stage of 
amyloidosis at the time of TBI.  
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5 The effect of alterations to the neurofilament cytoskeleton on 
the axonal response to diffuse traumatic brain injury 
 
5.1 Introduction 
TBI causes straining and shearing forces on the brain, which results in DAI 
(Adams et al., 1982, Gennarelli et al., 1982, Strich, 1956, Strich and Oxon, 
1961). DAI is characterized by neurite swellings representing impaired axonal 
transport as well as neuritic bulbs representing axonal disconnection (Hanell et 
al., 2014, Tang-Schomer et al., 2012, Tang-Schomer et al., 2010). The previous 
chapter identified axonal transport deficits using APP immunohistochemistry at 
24 hours following LFPI. Furthermore, Aβ was shown to co-accumulate with 
APP in diffusely injured axons. The accumulation of APP and Aβ within injured 
axons may be a mechanism by which TBI leads to increased Aβ plaque 
deposition, as seen in the previous chapter, and thus increases the risk of 
developing AD. 
 
The impairment of axonal transport and disconnection of axons following TBI is 
in part due to damage to the axonal cytoskeleton (Smith and Meaney, 2000, 
Tang-Schomer et al., 2012, Tang-Schomer et al., 2010). The axonal cytoskeleton 
is comprised of microtubules, actin filaments and NFs. Following TBI, breakage, 
disorganization and disassembly of microtubules causes interruption to axonal 
transport resulting in the accumulation of transported cargoes and thus axonal 
swellings (Tang-Schomer et al., 2012, Tang-Schomer et al., 2010). TBI may also 
cause degradation of NFs due to the activation of proteases, including calpain 
(Buki et al., 2003, Ma et al., 2013) as well as a reduction in the interfilament 
spacing of NFs, termed NF compaction (Pettus et al., 1994, Povlishock et al., 
1997). NF compaction has been hypothesized to be part of the same evolving 
axonal pathology as microtubule disassembly, ultimately leading to axonal 
transport deficits (Pettus et al., 1994, Povlishock and Pettus, 1996), but recent 
evidence suggests it occurs independently and is a separate injury phenotype 
(Marmarou et al., 2005, Stone et al., 2001). 
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NFs in the central nervous system are comprised of four subunits, NF heavy 
(NFH), NF medium (NFM), NF light (NFL) and alpha-internexin, which co-
polymerise into obligate heteropolymers forming intermediate filaments 
(reviewed in Yuan et al., 2012). NFs are exceedingly abundant in many axons 
and are expressed in a subset of neurons in the brain (Vickers and Costa, 1992, 
Kirkcaldie et al., 2002). The genetic deletion of the NFL protein has been shown 
to significantly alter the expression and distribution of the other NF subunits 
throughout the cortex, however cortical structure and cytoarchitecture remain 
apparently normal (Liu et al., 2013). 
 
In AD, the accumulation of NFs in dystrophic neurites is an early neuronal 
change associated with Aβ plaque formation (Vickers et al., 1996, Masliah et al., 
1993, Dickson et al., 1999) and neurons expressing NFs are selectively 
vulnerable to tau neurofibrillary tangle formation and degeneration (Mitew et al., 
2013b, Vickers and Costa, 1992, Vickers et al., 1994). Furthermore, the deletion 
of NFL in the APP/PS1 mouse model of AD has been shown to result in 
increased Aβ plaque deposition and enhanced dystrophic neurite formation 
(Fernandez-Martos et al., 2015). Thus, these studies demonstrate that the NF 
network is important in the neuronal and axonal responses to AD-associated 
pathology and perhaps etiology.  
 
Axons lacking NFL show reduced APP accumulation in damaged neurites and 
attenuated regeneration following in vitro localized axotomy (Blizzard et al., 
2013). However, the exact effect of ablating the NF network on the axonal 
response to diffuse TBI in vivo remains unknown. This chapter explores whether 
the deletion of NFL affects axonal transport deficits following TBI, as shown by 
APP immunohistochemistry. To this end, mice with homozygous deletion of 
NFL (NFLKO) and WT mice (NFLWT) were subjected to LFPI and changes in 
the accumulation and expression of APP were examined by 
immunohistochemical and biochemical assays.  	 	
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5.2 Materials and Methods 
 
5.2.1 Mice 
Male transgenic mice harbouring a disruption of the NFL gene 
(C57BL/6J×129Sv.NFL-/-) were a gift from Dr Jean-Pierre Julien (Université 
Laval, Canada) and were maintained as a homozygous colony (Zhu et al., 1997) 
by Dr Mala Rao (Nathan Kline Institute, New York). As most antibodies used to 
label axons by immunohistochemistry are directed against NF proteins, and this 
project was part of a larger study, the C57BL/6×129Sv.NFL-/- mice were crossed 
with YFPH transgenic mice (Jackson Laboratory, USA, Strain B6.Cg-Tg(Thy1-
YFP+/-)HJrs/J, Stock No. 003782) to obtain an F1 generation (NFL+/-.Thy1-
YFPH+/- and NFL+/-.Thy1-YFPH-/-). The F1 generation was then crossed to 
obtain transgenic mice with a disruption of the NFL gene and neuronal YFP 
expression (C57BL/6×129Sv.NFL-/-.Thy1-YFPH+/-) and with normal NFL gene 
expression and neuronal YFP expression (NFL+/+-.Thy1-YFPH+/-). In the studies 
included in this thesis both mice expressing neuronal YFP (YFPH positive, 
Thy1-YFPH+/-) and not expressing neuronal YFP   (YFPH negative, Thy1-
YFPH-/-) were used.  Therefore, the mice used in this study were NFLKO mice 
(either NFL-/-.Thy1-YFPH+/- (YFPH positive) or NFL-/-.Thy1-YFPH-/- (YFPH 
negative)) and NFLWT mice (either NFL+/+.Thy1-YFPH+/- or NFL+/+.Thy1-
YFPH-/-). All experimental procedures were undertaken on mice between the 
ages of 2-6 months and, due to time constraints on breeding, both male and 
female mice were utilized for some experiments. Table 5.1 outlines the genders 
and genotypes of the mice used in each set of experiments.  
 
5.2.2 Genotyping 
Mice were genotyped as specified in the Materials and Methods section 2.2. 
Specific primers to the genes YFP, NFL, neomycin phosphotransferase (present 
within the pMC1neoPoly A vector indicating deletion of NFL) and Tcrd (internal 
control) were used to determine the genotypes of mice used. Refer to Table 5.2 
for primer sequences and PCR product sizes.  
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Table 5.1 Genotypes of the mice used for experiments.  
Experiment NFL genotype Gender YFPH 
genotype 
Number 
LFPI 
Immunohistochemistry 
NFLKO 
male 
 
 
positive 
negative 
Total 
6 
- 
6 
NFLWT 
male 
 
 
positive 
negative 
Total 
2 
4 
6 
Sham 
Immunohistochemistry 
NFLKO 
male 
 
 
positive 
negative 
Total 
3 
- 
3 
NFLWT 
 
male 
 
 
positive 
negative 
Total 
4 
- 
4 
LFPI 
Western Blot 
NFLKO 
male 
 
 
female 
 
 
 
positive 
negative 
 
positive 
negative 
 
Total 
1 
2 
 
1 
2 
 
6 
NFLWT 
male 
 
 
female 
 
 
 
positive 
negative 
 
positive 
negative 
 
Total 
2 
1 
 
1 
2 
 
6 
Sham 
Western Blot 
NFLKO 
male 
 
 
female 
 
 
 
positive 
negative 
 
positive 
negative 
 
Total 
2 
1 
 
2 
1 
 
6 
NFLWT 
male 
 
 
female 
 
 
 
positive 
negative 
 
positive 
negative 
 
Total 
2 
1 
 
2 
1 
 
6 
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Table 5.2 Genotyping PCR primers. 
Gene Primer sequence Product Size (bp) 
YFP 
forward 5’- TCTGAGTGGCAAAGGACCTTAGG-3’ 
reverse 5’- CGCTGAACTTGTGGCCGTTTACG-3’ 
300 
NFL 
forward 5’-CAGCTTCATCGAGCGCGTGC-3’ 
reverse 5’-CGTCGGTGTTCTTGGCGGC-3’ 
589 
Neo 
Insert 
forward 5’-CTGAATGAACTGCAGGACGAG-3’ 
reverse 5’-GGCAAGCAGGCATCGCCATG-3’ 
413 
Tcrd 
forward 5’- CAA ATGTTGCTTGTCTGGTG3’-3’ 
reverse 5’- GTCAGTCGAGTGCACAGTTT-3’ 
200 
 
5.2.3 In vivo diffuse traumatic brain injury 
LFPI was performed as outlined in the Materials and Methods section 2.4. A 
mild injury severity of 1.25-1.35atm was used. Surgeries were performed by two 
trained individuals.  
 
5.2.4 Tissue preparation 
At 3 days post-injury, mice were terminally anaesthetized, transcardially 
perfused and tissue was prepared for either immunohistochemistry or Western 
blotting as outlined in the Materials and Methods section 2.4. For 
immunohistochemical studies serial 50µm coronal sections were cut on a 
vibratome (Leica VT1000). 
 
5.2.5 Immunohistochemistry 
Immunohistochemistry was performed as outlined in Materials and Methods, 
section 2.6.1. To detect DAI, a polyclonal rabbit anti-APP antibody was used 
followed by an Alexa 594-conjugated goat anti-rabbit IgG secondary antibody 
(refer to Table 2.1 in the Materials and Methods for antibody dilutions and 
details).  
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5.2.6 Protein extraction and Western blotting 
Protein extraction and Western blotting was performed as outlined in the 
Materials and Methods section 2.7. For each sample, 20µg of protein was loaded 
onto the gel. The expression of APP was normalized to the loading control 
GAPDH and ImageJ software was used to measure the integrated intensity of 
bands (refer to Table 2.1 in the Materials and Methods section for antibody 
concentrations). Western blotting and quantification was performed blinded to 
treatment and genotype. 
 
5.2.7 Confocal microscopy and quantitation 
Confocal microscopy was performed on a Perkin-Elmer Ultraview VOX 
confocal imaging system using Volocity 6.3 software for image capture and 
stitching (10% overlap, no corrections). APP accumulations within the white 
matter tracts were imaged using a 20x objective. Analysis was performed on the 
deep cortical white matter tracts, including the cingulum, from the midline to the 
end of the lateral ventricle/hippocampus on a single plane between bregma – 
0.34 and bregma – 1.94 for 3 sections per mouse. APP-positive axonal profiles 
within the region of interest were counted manually using ImageJ. The region of 
interest was then measured using ImageJ, and counts expressed as the number of 
APP-positive axonal profiles/mm2. Confocal microscopy and analysis were 
performed blinded to genotype.  
 
5.2.8 Statistical analysis 
Data were analysed using SPSS (Version 19, IBM). For axonal profile counts, 
Student’s two-tailed t-test was used to compare injured NLFKO to injured 
NFLWT mice. For the analyses of Western blot data, Student’s two-tailed t-test 
showed no sex difference in any of the groups, and thus male and female data 
was pooled for ANOVA analysis. An ANOVA with the factor variables of 
treatment (LFPI or sham) and genotype (NFLKO or NFLWT) as well as a full 
factorial ANOVA looking at the interaction between these two these two factors 
was performed. All data are expressed as means ± standard error of the mean 
(SEM) with significance set at p < 0.05. 
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5.3 Results 
 
5.3.1 LFPI characterisation  
The parameters of this LFPI model did not cause obvious cortical loss in 
NFLKO or NFLWT mice. The mean impact pressure pulses for each group were 
1.33 ± 0.03atm for the NFLKO mice and 1.31±0.02atm for the NFLWT mice, 
and were not significantly different (p>0.05, Figure 5.1). This injury did not 
induce prolonged unconsciousness, with the animals able to right themselves 
immediately following the injury.  APP-positive axonal profiles were observed 
in the corpus callosum, cingulum, external capsule and hippocampus (Figure 
5.2). APP-positive axonal profiles appeared most concentrated in the corpus 
callosum adjacent to the lateral ventricle, the cingulum and the external capsule 
(Figure 5.2). APP-positive axonal profiles were not seen in sham treated NFLKO 
or NFLWT mice (Figure 5.2).  
 
5.3.2 NFL deletion affects the number of APP-positive axonal profiles in 
white matter tracts at 3 days post-injury. 
It is well established in the literature that the accumulation of APP within axons 
is indicative of DAI (Gentleman et al., 1993, Tang-Schomer et al., 2012). 
However, it has been shown that axonal accumulations of APP rarely co-localise 
with intra-axonal NF compaction suggesting they are separate TBI-induced 
pathologies (Marmarou et al., 2005, Stone et al., 2001) and thus, the role of NFs 
in DAI and APP accumulation remains unknown. Therefore, the effect of NFL 
deletion on the axonal response to injury was examined by APP 
immunohistochemistry. The number of APP-positive axonal profiles per mm2 
within the corpus callosum, cingulum and external capsule was counted. 
Following LFPI, there were significantly more APP-positive axonal 
profiles/mm2 in NFLKO mice than in NFLWT mice (328.3 ± 46.1/mm2 vs 182.5 
± 42.7mm2, p<0.05, Figures 5.3A and B).  
 
 
 
Figure 5.1 Average injury severity as determined by the fluid pressure pulse 
delivered in atm, did not vary between groups. There was no signficant 
difference (p>0.05) in the average pressure pulse delivered between any of the 
injured groups. Bars represent means ± standard error.
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Figure 5.2 APP-positive axon pathology in NFLKO and NFLWT mice at 
3 days post-LFPI. APP immunohistochemistry in the white matter tracts 
demonstrates APP-positive axonal profiles in NFLKO and NFLWT mice 
after LFPI. APP-positive axonal profiles are not seen in the white matter 
tracts of sham treated NFLKO and NFLWT mice. Scale bar=100mm.
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Figure 5.3 NFLKO mice have more APP-positive axonal profiles in the white 
matter tracts compared to NFLWT mice at 3 days post-injury. (A) Representive 
sections labelled with APP. Yellow arrows indicate APP-positive axonal profiles. 
Scale bar=50mm. (B) LFPI caused significantly (p<0.05) more APP-positive 
axonal profiles  in NFLKO mice at 3 days post-injury. (C) Bars represent means 
± standard error. * denotes significance at p<0.05 for NFLKO versus NFLWT.
110
NFLKO NFLWT
0
100
200
300
400
500
N
o.
 A
PP
-p
os
iti
ve
 a
xo
na
l p
ro
fil
es
/m
m
2 *
NFLKO NFLWT
A
B
111
Chapter 5 – Results 
	 112	
5.3.3 NFL deletion does not alter the expression of APP within the cortex 
and underlying white matter tracts in injured or sham mice. 
To examine whether the deletion of NFL effects the expression of APP in injured 
and sham mice, Western blot analysis was performed. Ipsilateral cortical tissue 
including underlying white matter was dissected from injured and sham treated 
NFLKO and NFLWT mice. This analysis was performed on 3 male and 3 female 
mice from each genotype for each treatment. There was no significant effect 
(p>0.05) of gender for any group and thus the male and female mice were pooled 
together for further analyses. There was no significant effect of either treatment 
(p>0.05) or genotype (p>0.05) on APP protein levels at 3 days post-injury 
(Figures 5.4A and B), nor any interaction between these factors (p>0.05). Thus, 
NFL deletion does not affect the expression of APP within the cortex and 
underlying white matter tracts in either sham-treated or LFPI-treated mice. 
  
Figure 5.4 NFL deletion does not effect APP expression at 3 days post-injury. 
(A) Representive Western blots for APP and the house keeping gene GAPDH. 
(B) There was no significant differences in APP expression between NFLKO 
or NFLWT mice with either injury or sham treatment (p>0.05). Bars represent 
means ± standard error.
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5.4 Discussion 
DAI is one of the most common and significant pathological changes produced 
by TBI, and has been proposed to be responsible for a substantial proportion of 
subsequent morbidity (Johnson et al., 2013b). Axons are particularly vulnerable 
to mechanical injury in brain trauma due to their highly structured arrangement 
in the white matter tracts and their viscoelastic properties (Smith and Meaney, 
2000). During TBI, inertial forces on the head result in rapid stretching of axons 
(Adams et al., 1982, Gennarelli et al., 1982, Strich, 1956, Strich and Oxon, 1961) 
culminating in damage to the axonal cytoskeleton and impaired axonal transport 
(Tang-Schomer et al., 2012, Tang-Schomer et al., 2010). Impaired axonal 
transport due to the breakage and disassembly of microtubules causes 
accumulation of transported cargoes (Tang-Schomer et al., 2012, Tang-Schomer 
et al., 2010), however, the role of NFs in DAI is unclear. Thus, this study sought 
to determine the effect of NFL deletion on the axonal response to TBI. 
 
APP accumulation is a pathological hallmark of DAI (Gentleman et al., 1993, 
Tang-Schomer et al., 2012) because it is rapidly transported by kinesin-I (Kamal 
et al., 2000). Therefore, this study immunolabelled APP to explore the effect of 
NFL deletion on axonal transport after LFPI, finding that NFLKO mice have 
more APP-positive axonal profiles in the white matter tracts after LFPI than do 
NFLWT mice. This increase was not due to higher levels or enhanced 
upregulation of APP, since biochemical analyses showed no differences in APP 
levels between NFLKO and NFLWT mice either with or without LFPI.  
 
The increase in APP-positive axonal pathology in NFLKO mice may suggest that 
axons lacking a complete NF network are more mechanically vulnerable to the 
stretching caused by TBI, leading to enhanced microtubule breakage and APP 
accumulation. In support of this notion, previous evidence has shown that NFs 
can stretch more than three-fold, and may function as mechanical shock 
absorbers within axons (Kreplak et al., 2005).  Furthermore, studies have 
demonstrated that APP accumulation and NF compaction primarily occur 
independently and are thus distinct TBI-induced pathologies (Marmarou et al., 
2005, Stone et al., 2001). However, the results of the current study demonstrating 
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enhanced axonal APP accumulation following LFPI in NFL deplete neurons 
suggests the two pathologies may be linked. For example, NFs may protect 
microtubules from TBI-induced DAI and thus APP accumulation, but undergo 
compaction in the process and hence the pathologies are observed in separate 
axons/ axonal regions.  
 
The deletion of NFL has also been shown to increase the rate of fast anterograde 
and retrograde axonal transport of mitochondria and lysosomes in vitro (Perrot 
and Julien, 2009). Thus, the rate of APP axonal transport may also be increased 
due to NFL deletion, causing more rapid APP accumulation at points of axonal 
disruption following LFPI.  
 
Although the increase in APP-positive profiles in NFLKO mice may be due to 
differences in initial axonal damage or impaired axon transport, they may also be 
caused by an altered ability to repair cytoskeletal damage after injury. Axonal 
swellings occur where the cytoskeleton is disrupted (Tang-Schomer et al., 2012, 
Tang-Schomer et al., 2010), but if they do not grow to the point of disconnection 
then the damaged cytoskeleton may be repaired, and this ability may differ 
between NFL deficient and replete axons. As APP has been shown to begin 
accumulating in axons within hours after TBI (Pierce et al., 1996, Ciallella et al., 
2002, Sherriff et al., 1994) future studies should look at more acute time points 
to assess initial axonal damage and APP accumulation.    
 
In contrast to the current study, in vitro axotomy of NFLKO neurons resulted in 
reduced APP accumulation in damaged neurites compared to NFLWT neurons 
(Blizzard et al., 2013), but the primary axotomy used in this study would be 
expected to differ from the DAI of the current study, culminating in impaired 
axonal transport.  
 
Impaired axonal transport is an early pathological alteration in AD, and evidence 
suggests that it may acutely and chronically facilitate the development of Aβ 
plaques and thus AD (Stokin et al., 2005). A recent study has demonstrated that 
NFL deletion results in increased Aβ plaque deposition in APP/PS1 mice 
(Fernandez-Martos et al., 2015). Data from this thesis has shown the co-
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accumulation of APP with Aβ in diffusely injured axons and increased Aβ 
plaque deposition after LFPI in APP/PS1 mice. Thus, these data in combination 
with the current study demonstrating enhanced APP accumulation after LFPI in 
NLFKO mice suggest that increased axonal transport deficits may underlie the 
enhanced Aβ plaque deposition shown in NFLKO APP/PS1 mice in the previous 
study. 
 
A limitation of this study is the sole use of APP as a marker for axonal damage. 
Most antibodies used to label axons by immunohistochemistry are directed 
against NF proteins, but they could not be used in this study because the NFLKO 
mice have altered expression of the other NF subunits (Liu et al., 2013). Hence, 
to visualize axons the NFLKO mice were crossed with mice expressing yellow 
fluorescent protein (YFP) in a subset of cortical layer V pyramidal neurons (Feng 
et al., 2000). However, due to low breeding yields, insufficient YFP×NFLKO 
mice were available. Thus, a mixture of YFP positive and negative mice were 
utilized in these experiments, and the analysis was restricted to APP as a marker 
of axonal damage.  
 
The number of YFP positive and negative mice used in this study was not large 
enough to test if YFP expression had an effect on the axonal response to injury. 
However, the proportion of axons expressing YFP is so low that axonal 
swellings were rarely both APP and YFP positive (Hanell et al., 2014); thus it is 
unlikely that YFP expression altered the number of APP-positive axonal profiles. 
Nonetheless, this is a limitation of the study, which should be addressed in future 
studies. Further experiments analyzing both YFP- and APP-positive axonal 
injury will give a more complete understanding of how perturbation of the NF 
cytoskeleton affects the axonal response after TBI.  
 
The biochemical analyses in this study utilised both male and female mice, 
which was also due to the time constraints of breeding. Previous studies have 
shown that sex hormones can affect certain aspects of the response to TBI 
(reviewed in Marklund and Hillered, 2011), however the results of the current 
study show no effect of gender on APP levels in either NFLKO or NFLWT 
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mice. Furthermore, the use of both genders may be viewed as a strength, as it 
increases the generalizability of the results (Prendergast et al., 2014). 
 
In conclusion, this study highlights the importance of intermediate filaments in 
the axonal response to TBI, particularly their role in impaired axonal transport. 
This thesis has demonstrated that TBI results in intra-axonal APP and Aβ 
accumulation and has shown that diffuse TBI can accelerate Aβ plaque 
deposition. The current study has shown that altering the axonal NF cytoskeleton 
exacerbates impaired axonal transport following LFPI as indicated by increased 
axonal APP accumulations. Thus, these results suggest, there is a direct 
relationship between NF networks and APP transport and/or processing. As 
axonal transport deficits are implicated in much of the morbidity following TBI 
(Johnson et al., 2013a), including Aβ plaque deposition (Johnson et al., 2010), 
NFs may be a good therapeutic target for the treatment of TBI and the ensuing 
neurodegenerative cascade.  
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6 Discussion 
 
TBI is an important health problem worldwide, resulting in significant morbidity, 
disability and death (Maas et al., 2008, Roozenbeek et al., 2013). In high-income 
countries TBI is the leading cause of disability and mortality in young people and 
poses a substantial economic burden due to the costs associated with ongoing 
care for people with cognitive deficits (Maas et al., 2008, Roozenbeek et al., 
2013).  
 
TBI can cause persistent neurodegeneration within the brain many years after the 
initial insult (reviewed in Faden and Loane, 2015) and currently there are no 
effective therapeutics to intervene in the process. TBI is a risk factor for AD 
(Fleminger et al., 2003, French et al., 1985, Graves et al., 1990, Guo et al., 2000, 
Heyman et al., 1984, Kondo et al., 1994, Mayeux et al., 1993, Mortimer et al., 
1991, O'Meara et al., 1997, Plassman et al., 2000, Rasmusson et al., 1995, 
Schofield et al., 1997, Sullivan et al., 1987, Wang et al., 2012) and repetitive TBI 
can result in the development of CTE, a disease with many AD-like features 
(Corsellis et al., 1973, Martland, 1928, McKee et al., 2009). Currently, there is 
no cure for AD or CTE and existing therapies are of little efficacy, thus efforts to 
prevent disease development are of the upmost importance.  
 
To develop therapies for AD, we first must understand its etiology. Uncovering 
the molecular mechanisms underlying the relationship between TBI and AD may 
lead to interventions to prevent both ongoing neurodegeneration after TBI and 
the development of AD.  
 
Aβ plaques are one of the pathological hallmarks of AD (Braak and Braak, 1991) 
and are associated with many of the neurodegenerative changes underlying the 
disease (Mitew et al., 2013a, Mitew et al., 2010, Dickson and Vickers, 2001, 
Hardy and Allsop, 1991, Kuchibhotla et al., 2008, Vickers et al., 1996). Aβ 
plaques also occur in approximately 50% of CTE cases and these cases were 
shown to be a more aggressive, distinct subtype of the disease with a worse 
clinical outcome (Stein et al., 2015). Mutations in the APP gene that result in 
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enhanced genesis of the Aβ peptide cause familial AD (Bagyinszky et al., 2014, 
Goate et al., 1991). Therefore, one mechanism by which TBI may lead to the 
development of AD is through altering Aβ dynamics.  
 
As previously discussed, studies have shown the presence of Aβ plaques in 
surgically excised and post-mortem brain tissue from severe TBI cases (Roberts 
et al., 1991, Roberts et al., 1994, DeKosky et al., 2007, Ikonomovic et al., 2004). 
However, whether mild and moderate TBI leads to the development of Aβ 
plaques and whether these plaques persist after injury remains unclear. Animal 
models of experimental TBI have also been used to explore the relationship 
between TBI and Aβ plaque dynamics. However, the results of these studies 
have been conflicting with evidence for increased (Uryu et al., 2002), decreased 
(Nakagawa et al., 1999, Nakagawa et al., 2000) and unchanged (Smith et al., 
1998) Aβ plaque deposition after TBI. Therefore, the central aim of this thesis 
was to determine the effects of TBI on Aβ plaque dynamics.  
 
Beta-amyloid deposition following traumatic brain injury 
This thesis utilized two models of TBI to investigate the effects of different types 
of injury on Aβ plaque deposition. The first model was a focal penetrative brain 
injury to the somatosensory cortex, which causes localized inflammation, 
neovascularization, tissue remodeling and glial scar formation, without 
widespread secondary pathology (Blizzard et al., 2011, King et al., 2001).  The 
second model was the LFPI model, which induces both focal and diffuse TBI 
(Alder et al., 2011, Xiong et al., 2013) allowing the effects of widespread injury 
with secondary pathological changes, on Aβ plaque deposition to be examined. 
 
Focal cortical TBI did not alter Aβ plaque load at 24 hours or 7 days post-injury 
in APP/PS1 mice injured either prior to amyloidosis (3-months of age) or during 
plaque deposition (9-months of age). Although it is possible that Aβ plaque 
deposition may have been altered at a more protracted time point after injury, 
this is unlikely since by 7 days post-injury substantial tissue remodeling and glial 
scar formation has occurred and the lesion is resolving (this study, Blizzard et al., 
2011). Therefore, the results of this study indicate that focal brain injury is 
unlikely to affect the onset or progression of Aβ plaque deposition post-injury.  
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In contrast to the focal brain injury model used in aim 1, the LFPI model of 
diffuse TBI used in aim 2, did alter Aβ plaque deposition post-injury. The results 
demonstrated that diffuse TBI altered Aβ plaque deposition in the cortex 
bilaterally at 30 days post-injury, dependent on the stage of amyloidosis at the 
time of injury. LFPI prior to the onset of amyloidosis (at 3-months of age) 
accelerated plaque deposition, whereas LFPI during amyloidosis (at 6-months of 
age) reduced plaque deposition.  
 
Total Aβ plaque load, but not fibrillar plaque load was reduced in 6-month-old 
APP/PS1 mice after LFPI. Whether or not LFPI caused reduced deposition or 
enhanced clearance of Aβ plaques remains to be elucidated. Studies suggest that 
non-fibrillar/diffuse Aβ is more readily cleared than fibrillar Aβ (Wang et al., 
2011, Levites et al., 2006). Thus, the reduction in total, but not fibrillar Aβ 
plaque load seen in the current study may be due to the clearance of existing or 
newly formed diffuse Aβ plaques. Future experiments should investigate the 
mechanism/s by which LFPI caused a reduction in Aβ plaque load including 
removal by glia, the recruitment of BMDM, changes to the glymphatic clearance 
of Aβ and the activation of Aβ-degrading enzymes such as neprilysin. This may 
lead to the development of new therapeutics for AD, with the ability to remove 
or reduce the deposition of Aβ plaques in the brain. Furthermore, as the LFPI 
causes both acute and chronic pathological alterations to the brain post-injury 
(Spain et al., 2010, Thompson et al., 2005), a limitation of this study is Aβ 
plaque load after LFPI was only evaluated at the time point of 30 days post-
injury. Future studies should address this limitation by examining changes in A
 plaque load at more acute and chronic time points after LFPI. 
 
The differing effects of the two injury models on Aβ plaque deposition may be 
due to the more widespread and evolving secondary pathology induced by the 
LFPI model (Alder et al., 2011, Xiong et al., 2013) in comparison to the focal 
brain injury model (Blizzard et al., 2011). Previous studies on transgenic mouse 
models of AD demonstrating changes in Aβ plaque deposition post-injury 
(Nakagawa et al., 1999, Nakagawa et al., 2000, Uryu et al., 2002) have utilized 
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the CCI model of TBI, which like the LFPI model, induces both focal and diffuse 
brain damage (reviewed in Xiong et al., 2013). One major difference between 
focal and diffuse TBI is the presence of DAI in the latter (Adams et al., 1982, 
Gennarelli et al., 1982, Strich, 1956, Strich and Oxon, 1961), which may be 
integral in TBI-induced changes in Aβ plaque deposition and will be discussed 
below. Thus, this thesis and previous literature (Nakagawa et al., 1999, 
Nakagawa et al., 2000, Uryu et al., 2002) support the notion that diffuse brain 
injury may be necessary for the modulation of Aβ plaque deposition post-TBI.  
 
Axonal injury and its role in traumatic brain injury-induced Alzheimer’s 
disease risk 
No intra-axonal accumulations of Aβ were seen following the focal cortical brain 
injury utilized in aim 1. However, LFPI prior to amyloidosis caused the co-
accumulation of Aβ with APP in diffusely injured axons. The accumulation of 
APP following TBI is due to damage to the axonal cytoskeleton resulting in 
impaired axonal transport (Tang-Schomer et al., 2012, Tang-Schomer et al., 
2010). The co-accumulation of Aβ may be due to aberrant generation of Aβ at 
sites of impaired axonal transport as studies have demonstrated that it co-
accumulates with its amyloidogenic processing enzymes as well as Aβ (Chen et 
al., 2009, Uryu et al., 2007). Intra-axonal accumulations of Aβ may seed plaque 
formation due to its localized release into the brain parenchyma. Thus, the 
increase in Aβ plaque deposition demonstrated in mice subjected to LFPI prior to 
amyloidosis, in the current study, may be due to TBI-induced impaired axonal 
transport. In support of this hypothesis, it has been shown that impairment of 
axonal transport by the inhibition of kinesin-I results in enhanced Aβ plaque 
deposition in a mouse model of AD (Stokin et al., 2005). Furthermore, axonal 
swellings morphologically similar to those seen following TBI have been 
demonstrated in early AD and in transgenic mouse models of AD (Stokin et al., 
2005). Together, these data indicate that impaired axonal transport may be an 
initiating factor in the development of Aβ plaques.  
 
As mentioned previously TBI induces damage to components of the axonal 
cytoskeleton. Following TBI, microtubules undergo breakage, disassembly and 
disorganization (Tang-Schomer et al., 2012, Tang-Schomer et al., 2010) and NFs 
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are shown to accumulate within axonal swellings (Chen et al., 1999) as well as 
undergo degradation (Buki et al., 2003, Ma et al., 2013) and compaction (Pettus 
et al., 1994, Povlishock et al., 1997). In AD the accumulation of NFs is an early 
neuronal change associated with Aβ plaque formation (Vickers et al., 1996, 
Masliah et al., 1993, Dickson et al., 1999). Additionally, a study from the same 
laboratory group has shown that altering the axonal cytoskeleton by deletion of 
NFL resulted in enhanced Aβ plaque deposition and exacerbated the 
development of a subset of dystrophic neurites in the APP/PS1 mouse model of 
AD (Fernandez-Martos et al., 2015). Thus, these studies demonstrate that the NF 
network is important in the axonal responses to TBI and AD-associated 
neurodegeneration. Therefore, the third aim of this thesis was to examine the 
effect of altering the NF cytoskeleton on the axonal response to TBI. 
 
The results of this thesis demonstrated that the deletion of NFL caused increased 
APP accumulation in axons of the white matter tracts after LFPI, yet no overall 
increase in the expression of APP. This indicates that altering the NF 
cytoskeleton does affect TBI-induced impaired axonal transport. NFs are 
suggested to perform as mechanical shock absorbers within axons (Kreplak et al., 
2005) and thus the deletion of NFL, which also results in reduced expression of 
the other NF triplet proteins (Liu et al., 2013), may result in axons that are more 
vulnerable to the tensile forces imparted by TBI leading to more microtubule 
damage. 
 
However, whether the increased amount of intra-axonal APP accumulations 
demonstrated was directly due to the reduction in NF content remains unknown. 
Studies have demonstrated that the deletion of NFL causes increased β-tubulin 
expression (Liu et al., 2013) as well as enhanced axonal transport rates (Perrot 
and Julien, 2009), which both may play a role in APP accumulation after TBI. 
Thus future studies should investigate the mechanism/s by which NFL deletion 
caused increased axonal pathology. This may elucidate new therapeutic targets 
for attenuating axonal damage, axonal APP and Aβ accumulation and ongoing 
neurodegeneration after TBI. 
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The glial response to traumatic brain injury in the setting of Alzheimer’s 
disease-related pathology 
The studies included in this thesis also investigated whether the brains response 
to TBI was enhanced or reduced in the setting of AD-related pathology. 
Following focal cortical brain injury there were no significant differences in the 
recruitment of activated microglia and astrocytes to the injury site between 
APP/PS1 and WT mice. These data were also supported by the results of the 
LFPI study, demonstrating no significant differences in the microglial or 
astrocytic responses between APP/PS1 and WT mice after injury. Therefore, 
these data indicate that microglia and astrocytes retain the ability to respond to 
traumatic insults despite the presence of AD-related neuroinflammation. 
 
At 30 days post-LFPI there was also no difference in the percent area occupied 
by microglia or astrocytes in sections of the cortex from injured versus sham-
treated APP/PS1 mice. There were however, changes in Aβ plaque deposition, 
which differed dependent on the stage of amyloidosis at the time of injury. It is 
possible that following LFPI there were differences in the phenotypes of 
microglial and/or astrocytes resulting in differential modulation of Aβ plaque 
deposition post-injury. Furthermore, changes in glial cells may have been 
apparent at early time-points post-injury. These limitations should be addressed 
in future studies to more fully understand the role of glial cells in A plaque 
formation and removal following TBI. 
 
Synaptic changes following traumatic brain injury in the setting of 
Alzheimer’s disease-related pathology 
Synaptic changes after focal cortical brain injury were also investigated in the 
setting of amyloidosis. The loss and recovery of synaptophysin immunoreactivity 
after focal cortical brain injury did not differ between APP/PS1 and wild-type 
mice suggesting that the synaptophysin loss seen in the APP/PS1 mouse model 
(Mitew et al., 2013a) occurs via specific AD-related neuropathological 
mechanisms. Additionally, these data indicate synaptic plasticity may still be 
able to occur in the brain despite the presence of AD-related pathology.  
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Synaptic alterations and cognitive deficits were not quantified following LFPI in 
this thesis. Although alterations in Aβ plaque deposition were seen following 
LFPI, whether these changes were associated with altered cognitive decline or 
synaptic plasticity was not elucidated. Previous studies have shown that Aβ 
plaque load does not correlate well will cognitive deficits in AD, however 
synaptic loss does (reviewed in Arendt, 2009). As synaptic loss and cognitive 
changes occur in both AD (Mitew et al., 2013a, reviewed in Arendt, 2009) and 
TBI (McAllister, 2011, Gao and Chen, 2011, Ding et al., 2009) future studies 
should quantify synaptic changes and cognition after TBI in mice at different 
stages of amyloidosis. This will provide important information on the 
interactions between AD-related synaptic alterations, TBI-induced synaptic 
changes and cognitive deficits after injury. 
 
Transgenic mouse models of Alzheimer’s disease in traumatic brain injury 
research 
The main limitation that must be taken into account when interpreting the results 
of this thesis is the use of a transgenic mouse model of AD. The results of the 
studies in this thesis give evidence for altered Aβ plaque deposition following 
TBI on the background of genetic susceptibility. Although most people do not 
have dominant AD causing mutations, many do develop Aβ plaques, and AD 
with ageing. WT mice however, do not form Aβ plaques with ageing (Selkoe, 
1989) or following TBI (Bramlett et al., 1997, Ciallella et al., 2002, Iwata et al., 
2002, Masumura et al., 2000, Pierce et al., 1996) and thus transgenic AD mouse 
models are necessary for examining the role of TBI in A plaque formation. As 
the aim of this thesis was to uncover the effects of TBI on AD pathology and 
APP and A dynamics, not AD in its entirety, the APP/PS1 mouse of AD 
amyloidosis is an appropriate model. AD mouse models will continue to be a 
useful tool in investigating the mechanistic links between TBI and the 
development of AD-related pathology. 
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Conclusion 
In conclusion, this thesis has expanded our knowledge of the effects of TBI on 
Aβ plaque dynamics, strongly suggesting that diffuse, but not focal TBI can alter 
the onset and progression of Aβ plaque deposition after injury. The results 
indicate that the stage of amyloidosis at the time of TBI effects whether or not 
Aβ plaque deposition increases or decreases and gives evidence supporting the 
role of the impaired axonal transport in the genesis of Aβ plaques. It indicates 
that the brain can respond to traumatic insults despite AD-related neuropathology 
and highlights the role of the NF network in axonal injury and impaired axonal 
transport, providing a potential therapeutic target to prevent TBI-induced 
neurodegeneration.   
6.1 Summary of the main findings of this thesis 
• Focal cortical TBI does not affect the onset or progression of Aβ plaque 
deposition in the APP/PS1 mouse model of AD prior to the onset of or 
during amyloidosis. 
• Diffuse TBI causes the intra-neuronal and intra-axonal accumulation of 
APP and Aβ acutely after injury in APP/PS1 mice, whereas focal cortical 
TBI does not. 
• Diffuse TBI accelerates the onset of amyloidosis in the APP/PS1 mouse 
model of AD as LFPI prior to amyloidosis caused an increase in fibrillar 
and total Aβ plaque deposition at 30 days post-injury. 
• Diffuse TBI during amyloidosis in APP/PS1 mice causes regression or 
slows progression of Aβ plaque deposition as LFPI caused a reduction in 
total Aβ plaque deposition at 30 days after injury.  
• Despite the background of AD-related neurodegeneration, APP/PS1 and 
WT mice have the same inflammatory response to focal cortical and 
diffuse TBI. 
• APP/PS1 and WT mice exhibit a similar synaptic response and equivalent 
levels of neuritic dystrophy following TBI.  
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• The deletion of NFL results in enhanced axonal transport deficits as 
indicated by intra-axonal APP accumulation after LFPI. 
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Appendix A – Commonly used solutions 		
0.27M sodium phosphate monobasic 
32.2g sodium phosphate monobasic (Sigma-Aldrich, S8282-500G) 
1000mL milli-Q® water 
 
0.16M sodium phosphate dibasic dihydrate 
28.4g sodium phosphate dibasic dehydrate (Sigma-Aldrich, S0876-1KG) 
1000mL milli-Q® water 
 
1.54M sodium chloride 
90g sodium chloride (Sigma-Aldrich, S3014-5KG) 
1000mL milli-Q® water 
 
0.01M Phosphate buffered saline (PBS)  
10mL of 0.27M sodium phosphate monobasic  
40mL of 0.16M sodium phosphate dibasic dihydrate  
100mL of 1.54M sodium chloride  
850mL milli-Q® water 
 
0.2% PBS Azide 
1g sodium azide (Sigma-Aldrich, S2002-500G)  
500mL 0.1M PBS 
 
0.01% Sodium Azide 
10mL 0.2% sodium azide 
190mL 0.01M PBS 
 
Antibody Diluent – 0.3% Triton-x-100 in 0.1MPBS 
600ul Triton-X-100 (Sigma-Aldrich, X-100-500ML) 
200mL 0.1M PBS 
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PBSX 0.25% Triton-X-100 in 0.1M PBS 
250ul Triton-X-100 
100mL 0.1M PBS 
 
10x TBS 
60.5g Trizma Base (Sigma-Aldrich, T1S03-1KG) 
87.6g NaCl  
pH to 7.5  
Make up to 1L with deionized water. 
 
1xTBS 
100mL 10× TBS 
900mL 1×TBS 
 
TBST 
100mL TBS 10×  
900mL dH2O  1mL	Tween-20	(P2287-500ML) 
 
Artificial cerebral spinal fluid (aCSF) 
7.305g Sodium chloride 
0.372g Potassium chloride 
1.802g Glucose 
2.383g HEPES 
0.294g Calcium chloride 
0.493g Magnesium sulfate 
pH to 7.4, make up to 1L with milli-Q® water and filter sterilize. 
 
4% paraformaldehyde (PFA)  
20g paraformaldehyde (granular) (Electron Microscopy Sciences, 19210) 
500mL of 0.01M PBS 
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0.5M EDTA  
292.24g EDTA (Sigma-Aldrich, EDS-500G) 
pH to 8.0, make up to 500mL. 
 
50×TAE 
100mL 0.5M EDTA ph8.0 
242g Trizma base in 750mL milli-Q® water 
57.1ml glacial acetic acid 
Make up to 1L with milli-Q® water. 
 
1×TAE 
20mL 50×TAE 
980mL milli-Q® water 
Figure B1 Segmentation of a stitched montage image. (A) Stitched montage 
image with grid-like pattern prior to segmenting. (B) Image in (A) following 
segmentation. The grid-like pattern did not effect the segmentation of 
plaques in different regions across the grid-like patterned image. 
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Appendix B - Segmentation of a stiched montage image
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